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Development of a cost-effectiveness model for optimisation
of the screening interval in diabetic retinopathy screening
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Background: The English NHS Diabetic Eye Screening Programme was established in 2003. Eligible people
are invited annually for digital retinal photography screening. Those found to have potentially
sight-threatening diabetic retinopathy (STDR) are referred to surveillance clinics or to Hospital Eye Services.
Objectives: To determine whether personalised screening intervals are cost-effective.
Design: Risk factors were identified in Gloucestershire, UK using survival modelling. A probabilistic
decision hidden (unobserved) Markov model with a misgrading matrix was developed. This informed
estimation of lifetime costs and quality-adjusted life-years (QALYs) in patients without STDR. Two
personalised risk stratification models were employed: two screening episodes (SEs) (low, medium or
high risk) or one SE with clinical information (low, medium–low, medium–high or high risk). The risk factor
models were validated in other populations.
Setting: Gloucestershire, Nottinghamshire, South London and East Anglia (all UK).
Participants: People with diabetes in Gloucestershire with risk stratification model validation using data
from Nottinghamshire, South London and East Anglia.
Main outcome measures: Personalised risk-based algorithm for screening interval; cost-effectiveness of
different screening intervals.
Results: Data were obtained in Gloucestershire from 12,790 people with diabetes with known risk factors
to derive the risk estimation models, from 15,877 people to inform the uptake of screening and from
17,043 people to inform the health-care resource-usage costs. Two stratification models were developed:
one using only results from previous screening events and one using previous screening and some
commonly available GP data. Both models were capable of differentiating groups at low and high risk of
development of STDR. The rate of progression to STDR was 5 per 1000 person-years (PYs) in the lowest
decile of risk and 75 per 1000 PYs in the highest decile. In the absence of personalised risk stratification,
the most cost-effective screening interval was to screen all patients every 3 years, with a 46% probability
of this being cost-effective at a £30,000 per QALY threshold. Using either risk stratification models,
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screening patients at low risk every 5 years was the most cost-effective option, with a probability of
99-100% at a £30,000 per QALY threshold. For the medium-risk groups screening every 3 years had a
probability of 43 –48% while screening high-risk groups every 2 years was cost-effective with a probability
of 55–59%.
Conclusions: The study found that annual screening of all patients for STDR was not cost-effective.
Screening this entire cohort every 3 years was most likely to be cost-effective. When personalised intervals
are applied, screening those in our low-risk groups every 5 years was found to be cost-effective. Screening
high-risk groups every 2 years further improved the cost-effectiveness of the programme. There was
considerable uncertainty in the estimated incremental costs and in the incremental QALYs, particularly with
regard to implications of an increasing proportion of maculopathy cases receiving intravitreal injection
rather than laser treatment. Future work should focus on improving the understanding of risk, validating in
further populations and investigating quality issues in imaging and assessment including the potential for
automated image grading.
Study registration: Integrated Research Application System project number 118959.
Funding details: The National Institute for Health Research Health Technology Assessment programme.
ABSTRACT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
vi
Contents
List of tables xi
List of figures xv
Glossary xvii
List of abbreviations xix
Plain English summary xxi
Scientific summary xxiii
Chapter 1 Background 1
Introduction 1
Our research plan was divided into four phases 3
Planned inclusion/exclusion criteria 4
Proposed outcome measures 4
Other outcomes: key recommendations for further research 4
Approval by ethics committees 4
Research governance 4
Proposed time period for retention of relevant documentation 4
Patient and public involvement 5
Chapter 2 How the project has changed since the outline proposal was accepted 7
Timeline changes 8
Chapter 3 On-going literature review conducted by the research team 9
Chapter 4 Added value: relevant work conducted by members of the research
team prior to commencement of or during work on this Health Technology
Assessment project 11
Chapter 5 Phase 1: risk factor approach 13
Rationale 13
Data set 13
Methods 14
Results 15
Does the inclusion of cholesterol into the model improve the fit? 27
Classical risk factors for progression of diabetic retinopathy 30
Chapter 6 Phase 2: extension to ethnically diverse populations 31
Rationale 31
Data 31
Expected outcome 31
Potential limitations 31
Results 31
Validation of model by ethnic group 36
Conclusion 39
DOI: 10.3310/hta19740 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 74
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Scanlon et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
vii
Chapter 7 Phase 3: monitoring interval approach 41
Rationale 41
Data set 41
Overview of method 41
Expected outcome 41
Introduction 42
Methods 42
Model structure 43
Estimated over- and under-referrals attributable to screening 44
Results 44
Higher-risk patients 50
Conclusion 51
Estimation of the rate of progression 51
Estimation of misclassification rates 52
Comparison with external estimates 52
Evaluating different intervals of screening 53
Discussion 53
Chapter 8 Phase 4: cost-effectiveness of differing screening intervals in diabetic
retinopathy screening 55
Introduction 55
Objective 55
Existing research 55
Methods 56
Interventions under study 56
Model structure 58
Model inputs 59
Life expectancy 63
Health utility and quality-adjusted life expectancy 63
Health and social care resource use and costs 63
Social care costs: nursing/residential care home admission 66
Analysis 67
Sensitivity and uncertainty analysis 67
Results 68
Diabetic retinopathy screening for patients with diabetes 68
Cost-effectiveness of differing screening intervals by risk group as defined from the
results from two consecutive screening episodes 72
Cost-effectiveness of differing screening intervals by risk group as defined from the
results of the initial screening episode and baseline clinical risk factors 75
Conclusion 79
Chapter 9 Other research using the same data set 81
Chapter 10 Lay perspective 83
Mike Whatmore’s contribution 83
Mike Larkin’s contribution 83
Chapter 11 Conclusions 85
Recommendations 86
Future work 86
CONTENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
viii
Acknowledgements 89
References 93
Appendix 1 Patient Information Advisory Group approval of consent model 101
Appendix 2 Health economic screening questionnaire 103
Appendix 3 Ethical Committee approval 113
DOI: 10.3310/hta19740 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 74
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Scanlon et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
ix

List of tables
TABLE 1 Severe sight impairment or blindness in Gloucestershire 12
TABLE 2 The population data from the Office for National Statistics for
Local Government 14
TABLE 3 Recording of results within the data set 15
TABLE 4 Recording of smoking results within the data set 15
TABLE 5 Grading levels of the English NHS DESP 16
TABLE 6 Characteristics of the derivation and validation sets 17
TABLE 7 Hazard ratios and 95% confidence intervals for progression after fitting
number of eyes with mild NPDR (unadjusted for HbA1c or duration of diabetes)
and explanatory information which links type of diabetes to duration and HbA1c 18
TABLE 8 Results of Cox proportional hazards model time to STDR (R2, R3 or M1) 18
TABLE 9 Characteristics of highest and lowest risk groups in validation data set
that are included in the risk model 20
TABLE 10 Characteristics of highest and lowest risk groups in validation data set
that are not included in the risk model 20
TABLE 11 First referable retinopathy detected by decile of risk in validation set 21
TABLE 12 Event rate in validation set: rate of progression to STDR 21
TABLE 13 Risk factors for progression to maculopathy M1 23
TABLE 14 Risk factors for progression to retinopathy R2 or R3 23
TABLE 15A Parameter estimates and HRs for the model with two screens plus
clinical data 24
TABLE 15B Parameter estimates and HRs for the model with two SEs only 24
TABLE 15C Parameter estimates and HRs for the model with one SEs plus CRF data 24
TABLE 16 AUC and 95% CI of the three models 27
TABLE 17A Patients who progressed to STDR with groups 1–3 separated. Light
green shading indicates those who move into a higher group when cholesterol is
added to the model and dark green shading indicates those who move into a
lower group 28
DOI: 10.3310/hta19740 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 74
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Scanlon et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xi
TABLE 17B Patients who did not progress with groups 1 to 3 separated. Light
green shading indicates those who move into a higher group when cholesterol is
added to the model and dark green shading indicates those who move into a
lower group 28
TABLE 17C Patients who progressed to STDR with groups 1 to 3 combined. Light
green shading indicates those who move into a higher group when cholesterol is
added to the model and dark green shading indicates those who move into a
lower group 29
TABLE 17D Patients who did not progress with groups 1 to 3 combined. Light
green shading indicates those who move into a higher group when cholesterol is
added to the model and dark green shading indicates those who move into a
lower group 29
TABLE 18 Validation data sets 32
TABLE 19 Validation results 34
TABLE 20 Results of fitting risk models to programme B 38
TABLE 21 Ethnicity coding in programme C 38
TABLE 22 Baseline characteristics of the modelling cohort 45
TABLE 23 Frequencies table of successive states observed in the Gloucester
screening data 46
TABLE 24 Fitted transition intensity matrix (shows estimated transition
intensities with 95% CIs) 47
TABLE 25 Fitted error matrix (shows estimated misclassification probabilities
with 95% CIs) 48
TABLE 26 Estimated HRs for change in (standardised) baseline variables 49
TABLE 27 Number of people referred by screening after baseline grade of
‘no detectable retinopathy’ and low-risk CRF 49
TABLE 28 Number of people referred by screening after baseline grade of
‘background retinopathy in one eye’ and low-risk CRF 49
TABLE 29 Number of people referred by screening after baseline grade of
‘background retinopathy in both eyes’ and low-risk CRF 50
TABLE 30 Number of people referred by screening after baseline grade of
‘no detectable retinopathy’ and high-risk CRF 50
TABLE 31 Number of people referred by screening after baseline grade of
‘background retinopathy in one eye’ and high-risk CRF 50
TABLE 32 Number of people referred by screening after baseline grade of
‘background retinopathy in both eyes’ and high-risk CRF 51
LIST OF TABLES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xii
TABLE 33 Demographic characteristics of patient subgroups at differing risks of
developing STDR based on the results of two consecutive SEs or one SE in
conjunction with CRF data 57
TABLE 34 Predictors of uptake rates for DR screening after initial screen 60
TABLE 35 Sensitivity and specificity of screening relative to true DR and
maculopathy grade 60
TABLE 36 Predictors of attendance to a HES assessment given diagnosis of STDR
(R2, R3 or M1) 61
TABLE 37 Predictors of treatment for STDR (R2, R3 or M1): probability of treatment 61
TABLE 38 Predictors of treatment for DR or maculopathy: treatment received 62
TABLE 39 Predictors of logMAR visual acuity 64
TABLE 40 Predictors of annual care costs after the initial DR screen 65
TABLE 41 Predictors of visual loss category 66
TABLE 42 Baseline characteristics of the simulated cohort 68
TABLE 43 Number of cases screened, referred, assessed and treated over the
lifetime of a cohort of 1000 people with diabetes 68
TABLE 44 Mean discounted costs and mean discounted outcomes of differing
screening intervals 69
TABLE 45 Cost-effectiveness of differing screening intervals 70
TABLE 46 Sensitivity analysis scenarios: impact of differing assumptions on ICERs 71
TABLE 47 Mean discounted costs and mean discounted outcomes of differing
screening intervals in low-risk patients (two consecutive SEs) 72
TABLE 48 Cost-effectiveness of differing screening intervals in low-risk patients
(two consecutive SEs) 73
TABLE 49 Mean discounted costs and mean discounted outcomes of differing
screening intervals in medium-risk patients (two consecutive SEs) 73
TABLE 50 Cost-effectiveness of differing screening intervals in medium-risk
patients (two consecutive SEs) 74
TABLE 51 Mean discounted costs and mean discounted outcomes of differing
screening intervals in high-risk patients (two consecutive SEs) 74
TABLE 52 Cost-effectiveness of differing screening intervals in high-risk patients
(two consecutive SEs) 74
DOI: 10.3310/hta19740 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 74
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Scanlon et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xiii
TABLE 53 Mean discounted costs and mean discounted outcomes of differing
screening intervals in low-risk patients (one SE+ CRF) 75
TABLE 54 Cost-effectiveness of differing screening intervals in low-risk patients
(one SE+ CRF) 76
TABLE 55 Mean discounted costs and mean discounted outcomes of differing
screening intervals in low- to medium-risk patients (one SE+ CRF) 76
TABLE 56 Cost-effectiveness of differing screening intervals in low- to medium-risk
patients (one SE+ CRF) 77
TABLE 57 Mean discounted costs and mean discounted outcomes of differing
screening intervals in medium- to high-risk patients (one SE+ CRF) 77
TABLE 58 Cost-effectiveness of differing screening intervals in medium- to
high-risk patients (one SE+ CRF) 77
TABLE 59 Mean discounted costs and mean discounted outcomes of differing
screening intervals in the high-risk group (one SE+ CRF) 78
TABLE 60 Cost-effectiveness of differing screening intervals in high-risk patients
(one SE+ CRF) 78
LIST OF TABLES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xiv
List of figures
FIGURE 1 Screening intervals for DR original study design 8
FIGURE 2 Receiver operating characteristic curve for validation data set 19
FIGURE 3 Validation data set: time to referable screening result by quintile of
risk (i.e. Group 1 contains those whose risk score is 0–20th centile, Group 2 is
21–40th centile, Group 3 is 41–60th centile, Group 4 is 61–80th centile, Group 5 is
81–100th centile) 19
FIGURE 4 First referable retinopathy detected by decile of risk in validation set 21
FIGURE 5 Model fitting for risk of progression to STDR 22
FIGURE 6 Progression to referable STDR by risk group in the three models 25
FIGURE 7 The proportion of each grade of retinopathy by risk group in those
found with referable retinopathy at the first SE where it was detected 26
FIGURE 8 Model comparison 27
FIGURE 9 Ranked centile of linear risk predictor for those with and without STDR 28
FIGURE 10 Validation in three English programmes 33
FIGURE 11 Severity of DR at event or censoring 35
FIGURE 12 ROC for model with clinical information and one SE 36
FIGURE 13 Validation in programme B using the risk stratification based on two SEs 37
FIGURE 14 Graphical representation of the model for progression of diabetic
eye disease 43
FIGURE 15 Screening pathway for diabetic patients offered DR screening 57
FIGURE 16 Clinical pathways of confirmed cases of STDR (R2, R3 or M1)
attending referral in HES 58
FIGURE 17 Model structure capturing the natural history component 58
FIGURE 18 Cost-effectiveness acceptability curve and EVPI per patient 70
FIGURE 19 Analysis of covariance analysis of proportion of sum of squares for
incremental QALYs saved and incremental costs explained by the uncertainty in
the model inputs 71
DOI: 10.3310/hta19740 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 74
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Scanlon et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xv

Glossary
6/6 vision The ability to perceive correctly an object or letter of a designated size from a distance of
6 metres – classified as normal visual acuity. Called ‘20/20’ vision in the USA.
Blindness (World Health Organization definition) Visual acuity that does not exceed 20/200 (6/60) in
the better eye with correcting lens.
Cotton wool spot Fluffy, white, opaque area caused by an accumulation of axoplasm in the nerve fibre
layer of the retina.
Diabetes mellitus The chronic condition in which there is an excess of glucose circulating in the
blood stream.
Diabetic retinopathy The microvascular complication of diabetes affecting the eye.
Exudate (or hard exudate) Small white or yellowish-white deposit with sharp margins, located typically
in the outer layers of the retina, but it may also be more superficial, particularly when retinal oedema
is present.
Focal (laser) Small treatment burn applied to defined localised areas of the retina to treat some
eye conditions.
Fovea A rod-free area at the centre of the retina, responsible for best central and colour vision.
Haemorrhage A red spot or blot, with irregular margins and/or uneven density, particularly when
surrounding a smaller central lesion considered to be a microaneurysm. Flame haemorrhages are superficial
haemorrhages just under the nerve fibre layer and blot haemorrhages are deeper haemorrhages.
Intraretinal microvascular abnormality Tortuous intraretinal vascular segments from dilated abnormal
retinal capillaries.
Light amplification by stimulated emission of radiation (laser) Different types of laser are used in the
imaging/diagnosis and treatment of many eye disorders. Low-powered laser instruments are used for
ophthalmic imaging and diagnostic purposes, whereas higher-powered treatment lasers are used to apply
retinal burns for focal, macular grid or pan-retinal photocoagulation retinal treatments.
Logarithm of the minimum angle of resolution (logMAR) This is a modern method used for the
measurement of visual acuity that has the same number of letters on each line, unlike the more common
Snellen chart.
Macula The area that surrounds the fovea, rich in neurosensory photoreceptor cones, responsible for
central vision.
Macular grid (laser) Small treatment burns applied in a grid pattern to the area around, but always
avoiding, the fovea. Used to treat eye conditions, such as vascular leakage, affecting the macular region.
Microaneurysm A red spot < 125 microns in diameter (approximately the width of a major vein at disc
margin) and with sharp margins.
New vessels at the disc New vessels at the optic disc or within 1-disc diameter of the optic disc margin.
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New vessels elsewhere New vessels greater than 1-disc diameter from the optic disc margin.
Pan-retinal photocoagulation (laser) The type of scatter laser treatment that is given to patients with
high-risk proliferative diabetic retinopathy, which usually involves 1200–2000 burns of 500-micron spot
size to an oval area of retina defined by a line passing two disc diameters above, temporal to and below
the centre of the macula and 500 microns from the nasal edge of the optic disc margin.
Pupil The opening in the centre of the iris that appears as a black dot through which light enters the eye.
Referable retinopathy The referable level in this study is when images in one or both eyes show the
features of pre-proliferative diabetic retinopathy (R2) or proliferative diabetic retinopathy (R3) and/or
maculopathy (M1) as defined by the grading form used in the English screening programme.
Retina The innermost layer of the eye containing photoreceptor cells and fibres connecting with the brain
through the optic nerve and nourished by a network of blood vessels.
Severely sight impaired (blind; UK definition) Acuity below 3/60; acuity better than 3/60 but below
6/60 with a very restricted visual field.
Sight impaired (partial sight; UK definition) From 3/60 to 6/60 with a full field; up to 6/24 with
moderate restriction of visual field [e.g. glaucoma; 6/18 or better with a gross field defect (e.g. hemianopia)
or a marked constriction of the field (e.g. retinitis pigmentosa)].
Sight-threatening diabetic retinopathy (STDR) In this study, this is the same as the referable level,
when images in one or both eyes show the features of pre-proliferative diabetic retinopathy (R2) or
proliferative diabetic retinopathy (R3) and/or maculopathy (M1) as defined by the grading form used in the
English screening programme.
Slit lamp biomicroscopy Examination technique using a slit lamp biomicroscope to examine the anterior
segment directly or posterior segment (retinal) detail through an indirect lens held between the slit lamp
beam and the eye being examined.
Type 1 diabetes Disease characterised by the absolute deficiency of insulin.
Type 2 diabetes Disease characterised by the relative deficiency of insulin associated with
insulin ‘resistance’.
Venous loop An abrupt curving deviation of a vein from its normal path.
Visual acuity Measurement of the ability of the eye to perceive the shape of objects in the direct line of
vision and to distinguish detail; generally determined by finding the smallest symbol on an eye chart that
can be recognised at a given distance.
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List of abbreviations
AUC area under the curve
BMI body mass index
CEAC cost-effectiveness acceptability
curve
CI confidence interval
CRF clinical risk factor
DESP Diabetic Eye Screening Programme
DM diabetes mellitus
DR diabetic retinopathy
ETDRS Early Treatment Diabetic Retinopathy
Study
EVPI expected value of perfect information
FN false negative
FNR false-negative rate
FP false positive
FPR false-positive rate
GP general practitioner
GP2DRS General Practice to Diabetic
Retinopathy Screening
HbA1c glycated haemoglobin
HES Hospital Eye Services
HR hazard ratio
ICER incremental cost-effectiveness ratio
IDF International Diabetes Federation
IQR interquartile range
IRMA intraretinal microvascular
abnormality
logMAR logarithm of the minimum angle
of resolution
MIQUEST Morbidity Information Query and
Export Syntax
NICE National Institute for Health and
Care Excellence
NPDR non-proliferative diabetic
retinopathy
NRI net reclassification improvement
PCT primary care trust
PDR proliferative diabetic retinopathy
PY person-year
QALY quality-adjusted life-year
ROC receiver operating characteristic
SE screening episode
SIGN Scottish Intercollegiate Guidelines
Network
STDR sight-threatening diabetic
retinopathy
UKPDS UK Prospective Diabetes Study
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Plain English summary
D iabetic eye disease [diabetic retinopathy (DR)] is a major cause of blindness in the working-agepopulation in the UK, but if sight-threatening retinopathy (STDR) is detected early by taking digital
photographs of the retina, treatment is effective and affordable.
Since the English NHS DR screening programme was introduced in 2003, fewer people have lost their
vision. Currently, the programme has a standard for photographing every patient annually, which may not
be necessary and puts a strain on resources.
In Gloucestershire, data from high-quality screening and general practitioner (GP) information were used to
evaluate what screening intervals could match patient conditions with existing resources.
Two models to identify people at greater risk of sight loss were designed; the first using only results from
screening data and the second using screening and GP data. Both models were checked using data
from other screening programmes.
Annual screening for all who have no indication of STDR was found to be unnecessarily expensive. If no
risk evaluation is used, screening this group (non-STDR) every 3 years was the most cost-effective option. If
a risk model is employed with personalised intervals, low-risk groups can be safely and effectively screened
every 5 years, whereas screening high-risk groups every 2 years further improves overall cost-effectiveness.
Benefits were assessed using a measure called quality-adjusted life-years, which combines both
life-expectancy and quality of life. There is uncertainty around some of the information used in
cost-effectiveness models, so further research would be needed to support this work.
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Scientific summary
Background
Diabetes mellitus affects over 3 million people in the UK, with over 2.6 million people in England alone.
Diabetic retinopathy (DR) is a common microvascular complication of type 1 and type 2 diabetes and
remains a major cause of vision loss and blindness in those of working age.
A national screening programme for diabetic eye disease was initiated in England during 2003 with
coverage across the country by 2008. The NHS Diabetic Eye Screening Programme is delivered by over
80 local screening programmes from both NHS and private providers.
The National Institute for Health and Care Excellence recommendations are for annual screening using
digital retinal photography for all patients with diabetes aged 12 years and over until such time as
specialist surveillance or referral to Hospital Eye Services (HES) is required. Going forward, this may be
unsustainable in light of a 5% annual increase in the number of people with diabetes and increasingly
constrained budgets. Although previous studies have assessed the cost-effectiveness of differing intervals
for DR screening, the evidence is mixed. Adapting screening intervals to reflect personalised risk profiles
could produce more cost-effective screening protocols.
During the screening episode (SE), best distance visual acuity is measured and digital photographs of the
retina are taken after pharmacological dilatation of the pupils. The retinal images are then assessed or
‘graded’ to identify all the features of DR in a multistage, quality-assured process. Eyes with retinopathy
are classified into one of three retinopathy grades or levels (R1 to R3 in increasing severity) depending on
the presence and severity of retinopathy features, combined with one of two categories depending on
whether the retinopathy is also affecting the patient’s macula (M1 cases) or not (M0 cases). Eyes without
any features of DR are classified as R0M0 (no retinopathy and hence no maculopathy). Seven categories
from R0M0 to R3M1 are therefore possible for each eye, as R0M1 (maculopathy without retinopathy) is a
disallowed category. The outcome for and subsequent management of the patient depends on the severity
of the more affected eye.
The four more severe categories (R2M0, R2M1, R3M0 and R3M1) are considered as having potentially
sight-threatening diabetic retinopathy (STDR) and require referral to HES as the primary outcome from
screening. Cases that are classified as R1M1 in one or both eyes are also classified as having STDR but are
sometimes offered interim review appointments in surveillance clinics or are referred directly to HES,
depending on severity and circumstances. Patients classified as having only ‘low-risk’ DR (R1M0) in one or
both eyes or no retinopathy (R0M0) in both eyes are offered an annual appointment for rescreening.
The R1M0 cases in one or both eyes, along with the bilateral R0M0 cases, represent the vast majority of
screened patients in each annual screening round.
Grading is subjective and is not an exact science, although all staff working in the national programme are
appropriately qualified and are quality assured. There is variation between graders and between the same
grader on a different day, as well as differences between programmes. Quality assurance procedures
are in place to minimise variation as much as possible. The sensitivity and specificity (or misclassification
rates) of the screening programme relies on accurate grading of photographs, but direct estimation of
misclassification is not always possible. In this project we have, however, estimated and incorporated
allowance for grading error using longitudinal data from an established screening programme with good
quality assurance and quality-control procedures and a stable well-trained workforce. We have modelled
the progression of DR from low-risk categories of bilateral R0M0, R1M0 in one eye or bilateral R1M0 to
the various states whereby referral to HES was required and/or laser treatment was indicated.
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Objectives
l To use eye screening, demographic and routinely collected clinical information from Gloucestershire
to develop a risk score for each patient and to identify patient groups whose risk of retinopathy
progression is low and whose screening interval can be safely extended.
l To extend our results to multiethnic populations using data sets from Nottinghamshire and South
London and a large data set of predominantly white Caucasian patients from East Anglia. We required
grading results from these data sets for at least a 3-year period. The risk score and algorithm was
tested against retinopathy grades in these sets where follow-up data were available.
l To model what the influence of the grading classification error is on over-referrals and under-referrals
and how that influence changes over time, taking into account sequential grading results and hospital
outcome results, comparing screening intervals that vary according to risk score against current
standard practice (annual screening for all patients) and other fixed-interval approaches.
l To determine whether assigning diabetic patients to differing DR screening intervals using a risk
estimation model is cost-effective when compared with the current English NHS Diabetic Eye Screening
Programme (i.e. annual screening for all people with diabetes).
Methods
An initial cohort of patients with at least two SEs was assembled from the Gloucestershire screening
programme and clinical data were collected from primary care electronic records. The cohort (n= 12,790)
was partitioned into derivation and validation sets using district council areas of primary care practice.
Proportional hazards were used to identify variables influencing time to progression to STDR in the
derivation set. The validation set was used to assess model fit by examining deciles of estimated risk.
Patients with no evidence of STDR were categorised into three groups or states: those with no DR (R0M0/
R0M0), those with mild non-proliferative DR (NPDR) in just one eye (R1M0/R0M0) and those with mild NPDR
in both eyes (R1M0/R1M0). Using the risk estimation algorithm the risk score in those with no evidence of
STDR was estimated and the risk for subsequent progression to STDR was calculated by quintile.
The model needed to be tested in other data sets, including those with more ethnic variation than the
predominantly white Caucasian patients that are found in the Gloucestershire population. Data were
obtained from three other English screening programmes and, for a subset of these patients, clinical data
were extracted from primary care.
We used a homogeneous hidden Markov model with seven states to estimate the probability of true
progression or regression and the conditional probability of an observed grade given the true grade
(misclassification). The stage or severity of retinopathy was assumed to progress as a function of duration
of diabetes and transitions were adjusted for baseline glycated haemoglobin (HbA1c) and type of diabetes.
A probabilistic decision analytic model, in the form of a hidden Markov model was developed to estimate
the costs and quality-adjusted life-years for each DR screening strategy over the lifetime of the patient.
Using data from the Gloucestershire screening programme, we obtained disease progression data and
associated changes in visual acuity; screening, referral, assessment and treatment uptake rates; and
secondary health-care costs. Other model parameters were obtained from the published literature.
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Results
The Gloucestershire derivation data set contained 7012 patients [56% male; 4.4% type 1 diabetes, 95.6%
type 2 diabetes; mean diabetes duration 1.9 years; mean age 65 years; HbA1c median 50mmol/mol (25–75th
centile 43 to 60mmol/mol), total cholesterol median 4.3mmol/l (25–75th centile 3.7 to 5.1mmol/l)] of whom
606 progressed to STDR by 5 years. The validation set comprised 5778 patients, with 490 progressing
to STDR.
Variables included were R1M0 in both eyes [hazard ratio (HR) 7.13, 95% confidence interval (CI) 5.84 to
8.70]; R1M0 in one eye only [HR 2.56 (95% CI 2.05 to 3.20)]; HbA1c [HR 1.28 (95% CI 1.3 to 1.34)]
per 10mmol/mol; duration of diabetes [HR 1.20 (1.16 to 1.24)] per 5 years since diagnosis and total
cholesterol [HR 1.08 (95% CI 1.05 to 1.19)] per mmol/l.
The risk estimates from the derivation set were applied to the validation set. The rate of progression to STDR
was 5 per 1000 person-years (PYs) in the lowest decile of risk and 75 per 1000 PYs in the highest decile.
In the cohort of 10,942 patients with at least three SEs and clinical information, in whom 1012 progressed
to STDR, the area under the receiver operating characteristic (ROC) curve for one screening plus clinical
information was 0.78 (95% CI from bootstrapping 0.75 to 0.80), for two screenings alone was 0.76
(95% CI 0.73 to 0.79) and for two screenings plus clinical information was 0.79 (95% CI 0.76 to 0.81).
The three English Programmes (East Anglia, South London and Nottinghamshire) used for further
validation of the model had 17,634, 1223 and 1083 people, respectively, in whom a baseline and one
further screening result and clinical risk factor data were available. There were few non-white patients in
East Anglia, but 31% and 18% of patients in South London and Nottinghamshire were of African or
African-Caribbean ethnicity, and 11% of patients in South London were of South Asian (predominantly
Indian) ethnicity.
In the three groups, the median duration of diabetes was 4.5 years (25–75th centile 1 to 8.7 years),
3.5 years (25–75th centile 1.3 to 6.7 years) and 2.9 years (25–75th centile 0.6 to 6.6 years), respectively;
median HbA1c was 55mmol/mol (25–75th centile 49 to 66mmol/mol), 52 (25–75th centile 45 to
64mmol/mol) and 53 (25–75th centile 46 to 63mmol/mol), respectively; and median follow-up from date
of index screening was 2.7 years (25–75th centile 2.0 to 3.0 years), 3.8 years (25–75th centile 2.0 to
6.8 years) and 4.2 years (25–75th centile 2.2 to 5.3 years), respectively.
The rate of detection of referable DR is elevated in those who were not screened promptly after diagnosis
of type 2 diabetes.
In the absence of personalised, risk-based screening intervals, screening every 3 years instead of annually
was found to be the most cost-effective strategy.
Using a risk-based strategy, the most cost-effective options were to screen those at low risk every 5 years
and those at medium and high risk of developing STDR every 3 and every 2 years, respectively.
With annual screening, the average discounted screening cost per patient was £273 with annual
screening, £144, £101 and £67 with screening every 2, 3 and 5 years. Mean costs associated with
assessment of referral at HES was also higher when screening annually (£114) than at 2, 3 and 5 years
(£70, £52 and £36, respectively). Combining all health and social care costs in the model, mean
discounted costs are £20,672 for annual screening, £20,490 for 2-yearly screening, £20,433 for 3-yearly
screening and £20,391 for 5-yearly screening.
From a total of 14,810 people, 68,992 examinations results were extracted from the screening service
database. The modelling data set consisted of 65,839 grades from 14,187 people. Observations were
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excluded if retinopathy or maculopathy grade were missing from either eye or were obviously duplicate
entries, and people were excluded if they only had one useable observation or did not have a baseline
HbA1c, serum cholesterol or duration of diabetes recorded. The median number [interquartile range (IQR)]
of examinations was 5 (3–6) and the median (IQR) interval between examinations was 1.04 years
(0.99–1.17 years).
When the prevalence of STDR is 7%, as per the baseline prevalence in the data, the false-positive (FP) rate
is estimated to be 1.6% and false-negative (FN) rate is 12.8%. When the prevalence of STDR is 15%, the
FP rate is 2.4% and FN 12.4%, and for a prevalence of 20%, the FP rate is 2.8% and FN rate 11.4%.
In East Anglia the rate of progression to STDR in the lowest risk quintile was 3 per 1000 PYs and in the
highest quintile was 74 per 1000 PYs; in South London the rate of progression to STDR was 1 in the
lowest risk quintile and 55 in the highest risk quintile; and in Nottinghamshire the rate of progression to
STDR was 2 in the lowest risk quintile and 79 in the highest risk quintile. The area under the ROC curve
was 0.84, 0.79 and 0.87, respectively, for the three groups.
Conclusions
In the absence of personalised, risk-based screening intervals, screening every 3 years is cost-effective.
Using a risk-based strategy, the most cost-effective options using Gloucestershire data were to screen
those at low risk every 5 years and those at medium and high risk of developing STDR/maculopathy
every 3 and every 2 years, respectively.
However, there is uncertainty in the evidence informing cost-effectiveness models, particularly in terms of the
natural history of disease progression, association between utility scores and visual acuity and the effectiveness
of treatment for diabetic maculopathy. There is also uncertainty concerning the annual marginal costs
attributable to treatment and assessments in the HES. Further research is required to confirm these results.
Risk estimation using either one SE plus clinical information or data from two SEs in this quality-assured eye
screening programme are equally powerful for categorising risk of subsequent development of STDR requiring
referral to a HES. These results were validated in other programmes.
Within each of the three programmes examined, the risk model discriminates well between those with very low
and those with high risk of progression to STDR. The algorithm would be suitable for calculation of personalised
screening intervals. Further validation in other screening programmes and ethnic groups is required.
Overall, misclassification of a photograph to a more advanced stage of any level of DR (including background
DR) is more common than misclassification into a lower grade. A modelling approach to estimating
misclassification rates is feasible using data from a screening programme but may be limited to progression
up to and no further than referral.
Study registration
This study is registered as Integrated Research Application System project number 118959.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Introduction
Diabetes affects over 3 million people in the UK. The treatment and complications of diabetes cost over
10% of the NHS budget.1 The International Diabetes Federation (IDF) published data2 in 2006 which
showed that diabetes affects 246 million people worldwide, with 46% of all those affected in the
40–59 years working age group. By 2009, IDF estimates showed that 285 million people were living with
the disease, with 90% of the burden caused by type 2 diabetes.3 According to the IDF, reasons for these
rises were driven by increases in life expectancy combined with sedentary lifestyles and increasing levels of
obesity. In England, quarterly returns to the Department of Health4 show that the number of people
identified by general practitioner (GP) practices as having diabetes had risen from approximately 1.4 million
people in 2003 to 2.4 million5 in the third quarter of 2011, the numbers having been rising by 120,000
per annum since accurate data from the screening services became available in 2008. The number in the
UK as a whole exceeded 3 million in 20136 and, at the same time, a further 850,000 people were
estimated to have undiagnosed type 2 diabetes mellitus (DM) by the charity Diabetes UK.6
Diabetic retinopathy (DR) results from damage to the small blood vessels in the back of the eye, which
generally occurs after about 10 years of diabetes and is the leading cause of blindness in the working age
population around the world,7,8 except in countries such as Iceland9 and England,10 where screening
programmes have become established. Two recent studies11,12 have shown that since 1985 people with
diabetes have experienced lower rates of progression to proliferative DR (PDR) and severe visual loss, probably
reflecting improvements in diabetes care. It is practical and affordable to treat13,14 sight-threatening diabetic
retinopathy (STDR) if detected early using screening with retinal photography. DR is treated effectively with
laser photocoagulation, although this has been found to be cost-effective only if retinopathy is detected
before irreversible damage takes place.13,15,16 Therefore, in order for DR treatment to be cost-effective,
diagnosis has to be timely. Published evidence has shown that screening for STDR is highly cost-effective.17–20
Since 2003, when the English NHS screening programme for DR was introduced, cases of loss of sight have
reduced. Offering annual DR screening to increasing numbers of patients puts immense strain on resources
and may not be necessary. National Institute for Health and Care Excellence (NICE) recommendations exist
but there is no evidence-based consensus as to the optimal frequency of testing for DR. The Scottish
Intercollegiate Guidelines Network (SIGN)21 reported that patients with diabetes with no detected
retinopathy could be screened every 2 years, with all others being screened at least annually. There have
been a number of studies22–25 that have modelled the possible effect of moving from annual to 2–3-year
intervals in patients with type 1 and type 2 diabetes using incidence data from screening programmes in
Iceland, Liverpool and Norwich. In 2007, Olafsdottir and Stefansson26 reported the 10-year experience of
biennial eye screening in patients with diabetes without retinopathy from Iceland, concluding that this
seems to be safe and effective.
In 2000, Vijan et al.27 reported on a cost–utility analysis of screening intervals for DR in patients with type 2
DM in an American population and concluded that annual retinal screening for all patients with type 2 DM
without previously detected retinopathy may not be cost-effective, and tailoring recommendations to
individual circumstances may be preferable.
An alternative modelling approach by Mehlsen et al.28 used clinical data from 5365 patients who had
undergone 23,324 examinations at the Department of Ophthalmology, Aarhus University Hospital and
concluded that a subset of known risk factors for development and progression of DR should be used to
construct a decision model for optimising screening intervals for DR.
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The current studies have not included factors such as the economic consequences of visual loss other than
legal blindness, the effect in ethnic or racial minority groups (the studies had mostly been in patients of
northern European extraction), and that long intervals between appointments may lead to difficulties in
maintaining follow-up with patients.29 A study30 in the Coventry area of the UK found that people of
South Asian ethnicity with diabetes were diagnosed at a younger age, had higher glycated haemoglobin
(HbA1c), systolic and diastolic blood pressure, and total cholesterol, and greater prevalence of DR and
maculopathy. The Diabetic Retinopathy In Various Ethnic groups (DRIVE) UK study, comprising patients in
screening programmes in West Yorkshire and South London, showed that DR and visual impairment were
more prevalent in people of African-Carribean and South Asian origin.31,32
In Gloucestershire, we have undertaken a preliminary analysis33 of screening data and know that we can
produce accurate and quality-assured screening results from the system because data already transferred
from GP practices have been of high quality. We have also been the pilot site for the national system
development and roll-out of software [General Practice to Diabetic Retinopathy Screening (GP2DRS)] for
transfer of demographic and risk factor data from GP practices to screening software systems. It is vital
that any modelling uses data that can be obtained easily from routine clinical care.
Grading of retinal photographs is not an exact measurement and, hence, intraobserver and interobserver
variability occurs in the grading.34 Screening and monitoring programmes for chronic conditions generate
both ‘false-positive’ (FP) tests and ‘false-negative’ (FN) tests. In the retinal screening programme, FP tests
correspond to people detected by the retinopathy screening service as requiring referral to hospital, but
who are subsequently found not to have retinopathy requiring treatment. FN tests correspond to people
with retinopathy who are missed by the screening service. FP and FN tests are an inevitable consequence of
inexact measurement.
Glasziou et al.35 showed that, even when there is no reference standard to determine which positive tests
in a database are FP, the proportion that are FP can be estimated from a model of the variability of the
test; similarly, so can the proportion of negative tests that are FN be estimated. The model has been
subsequently applied to blood pressure monitoring36 and it has been developed further for monitoring
HbA1c37 and microalbuminuria in diabetes.38 In general the model needs to allow for variation between
people, for average rate of change and variation in rate of change between people, and for the error rate
in any individual test; we have recently published full details of the methodology.39 These previous papers
used a normal distribution model for the error structure, but we have conducted pilot methodological
work showing that a logistic error structure can also be used successfully to model dichotomous outcomes.
As described previously, there is currently a well-documented epidemic of diabetes both in the UK and
worldwide. With the increase in diabetes, the economic burden that DR places on society is high.40,41 In the
UK, it was estimated in 2006 that the lifetime costs of dealing with retinopathy can be up to £237,000 per
person in the working age group, and that up to 50% of these costs are accounted for by the loss of
productivity as a result of blindness or vision impairment.42 Therefore, if 1000 cases of DR could be avoided
in the working age population, the potential savings to the government could be in excess of £237M.43
These compelling statistics encouraged the government to include annual DR screening in the National
Service Framework for diabetes.44
Conservative estimates of the costs of screening a patient with diabetes have been made of £26 per
patient (although costs may be higher if screening is carried out in GP surgeries, and the estimates ignore
costs to the patient in terms of travel costs and time off work). Although this cost might appear small,
there are about 2.6 million people with diabetes in England alone. Assuming an uptake of 71% of those
on the screening register (80% of those offered), these costs are of the order of £44M annually, without
taking into account the centralised costs of the management of the national programme. This is a very
sizeable financial resource, especially with the number of diabetes patients currently increasing at a rate of
over 100,000 cases a year,4 which will drive up screening costs even further. In addition, any improvement
in uptake would, obviously, have a corresponding impact upon these costs.
BACKGROUND
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The current study uses currently available data from screening software systems and GP systems. The
English NHS Diabetic Eye Screening Programme (DESP) has contracts with all the major GP software
suppliers, including Egton Medical Information Systems (EMIS) Ltd (Leeds, UK), In Practice Systems Ltd
(London, UK), iSOFT (formerly Torex; CSC Ltd. London, UK) and Microtest Ltd (Bodmin, UK). The Health
and Social Care Information Centre GP Systems of Choice contracts make available the demographic
transfer of data to screening programmes to invite people with diabetes for screening and to transfer risk
factor data. These contracts use a consent model that has been agreed with the Patient Information
Advisory Group and the National Information Governance Board.45 With the imminent availability of this
data to screening programmes in England there is an opportunity to provide cost-effective screening to
patients which takes into account their absolute risk of developing STDR.
If tailored screening intervals were found to be clinically effective and cost-effective through this research, the
logistical difficulties of delivering a national screening programme at a time of an epidemic of diabetes would
be reduced, without increasing risks for any individual patients of losing vision. In addition, any potential
savings might also give an opportunity to concentrate resources on persuading those most at risk to attend.
In addition, the evidence on the cost-effectiveness of different screening frequencies has been shown to
be mixed.46 A recent systematic review on the economic evidence of DR screening found three studies
addressing the issue of screening frequency,46 one performed in the USA and two in the UK.
Vijan et al.27 examined the cost-effectiveness of differing DR screening intervals for type 2 diabetes patients
in the USA. The authors employed a Markov model using quality-adjusted life-years (QALYs) as the main
outcome measure, with costs being assessed from a third-party payer perspective. Using the definition of
$50,000 per QALY gained as a cost-effective intervention, the authors reported that annual retinal
screening for all type 2 diabetes patients was not warranted on the basis of cost-effectiveness.
A UK study by Brailsford et al.47 also found similar results to that of Vijan et al.27 The study, which again
used decision modelling techniques to assess the cost-effectiveness of screening intervals in diabetes
patients (both types 1 and 2), found that a 30-month screening interval was the most cost-effective
option. However, in contrast to these two studies, another UK study by Davies et al.48 found that screening
diabetic patients less than once a year would not be any more cost-effective than every year. Davies et al.48
also based their study on a decision analytic model populated using results obtained from the published
literature. A finding common in both UK studies was that screening of type 1 diabetes patients was more
cost-effective than screening of type 2 diabetes patients.
There were, however, important limitations with both of the UK studies. Both studies used sight years saved as
their main outcome measure rather than a more generalisable health outcome, such as QALYs, that can be
readily compared across interventions and disease areas, aiding the decision process.49 In addition, the use of
QALYs captures the full impact of the disease, in this case sight loss or blindness, on patients’ lives. The two
studies also failed to include in their models the additional costs to the health-care service of patients losing
sight or going blind. Finally, data in these two studies were derived from a wide range of sources and diabetic
populations. As a result, numerous assumptions had to be made as to how best to synthesise the available data.
Our research plan was divided into four phases
Phase 1: Risk factor approach (see Chapter 5).
Phase 2: Extension to ethnically diverse populations (see Chapter 6).
Phase 3: Monitoring interval approach (see Chapter 7).
Phase 4: Cost-effectiveness of differing screening intervals in DR screening (see Chapter 8).
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Planned inclusion/exclusion criteria
The criteria for inclusion in these analyses were people with diabetes aged 12 years or above who have
been screened by the participating programmes of the English NHS DESP. We included patients who had
assessable retinal images from two or more screening episodes (SEs) and for whom we had sufficient
clinical information. The exclusion criteria as set by the English NHS DESP50 include the following:
1. patients with no perception of light in each eye
2. patients with a terminal illness
3. patients with physical disabilities making photographic screening impossible
4. patients with learning or mental disabilities making photographic screening impossible
5. patients who are currently under the care of an ophthalmologist and for whom a report on retinal
status has been provided to the screening service
6. patients who have chosen to opt out of screening.
Proposed outcome measures
To develop a risk-based algorithm for screening interval, cost-effectiveness and adverse events.
Other outcomes: key recommendations for further research
Approval by ethics committees
It had been agreed that risk factor data should be collected in the Department of Health-sponsored
GP2DRS project by screening services in the English NHS DESP and a national consent model was agreed
in England by the National Patient Information Advisory Group and subsequently by the National
Information Governance Board. Hence, we were advised that for the pilot of GP2DRS in Gloucestershire
comparing GP2DRS extracts with Morbidity Information Query and Export Syntax (MIQUEST) extracts, we
would not need to seek ethical approval. However, when it became clear that there were delays with the
roll-out of the GP2DRS system and that we would need to use MIQUEST extraction methods in other areas
to complete the research, we applied to the National Research Ethics Service Committee East of England –
Cambridge South and received a favourable opinion on 9 November 2012.
Research governance
The Nominated Sponsor of this research application is Gloucestershire Hospitals NHS Foundation Trust.
A Project Advisory Group was formed to oversee the progress of the research, and included an
independent chair (Professor John Sparrow), the lead researcher (Professor Peter Scanlon), the
co-applicants (Mrs Irene Stratton and Mr Steve Aldington), an independent statistician (Ms Catey Bunce),
an independent consultant ophthalmologist (Miss Clare Bailey), a lay representative (Mr Mike Whatmore),
and the research and development lead (Dr Julie Hapeshi) for the host Trust. Four of the Advisory Group
members (John Sparrow, Catey Bunce, Clare Bailey and Mike Whatmore) formed the Independent Trial
Steering Committee.
Proposed time period for retention of relevant documentation
The data from this study are pseudo-anonymised and will be kept for 8 years. It is likely that if any data are
required after that time then a new extraction would be required.
BACKGROUND
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Patient and public involvement
Mike Whatmore, a lay member of the Diabetes Research Network writing group ‘Screening for Diabetic
Retinopathy’, was involved in the original discussions on both reasons for non-attendance in DR screening
and screening intervals for DR and commented on the original application. A Diabetes UK Gloucestershire
lay member, Mike Larkin, read and commented on the application. Mike Larkin has had type 1 diabetes
since 1977 and has had DR since 1988. Mike Larkin is currently a member of a professional and lay group
within Diabetes UK, setting the research strategy for the charity for the next 5 years. Feedback on the
original application was also obtained from the Thames Valley Diabetes Local Research Network Patient
and Lay Involvement Group during the development of the application.
Mike Whatmore serves as a member of the Project Advisory Group and the Independent Trial Steering
Committee. Two other Gloucestershire lay members have regularly provided help and advice to the project
at the different stages.
In our proposal we sought the views of the Warwick Diabetes Research and Education User Group on the
original application and we were hoping to continue to consult with them but, unfortunately, as the
Coventry and Warwickshire Screening Programme were unable to continue with the research project,
it was not appropriate to continue using the resources of that user group.
Lay members contributed to this study report (in particular Mike Whatmore and Mike Larkin) and to the
dissemination of results both formally and in their multiple contacts with health professionals and
Diabetes UK.
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Chapter 2 How the project has changed since the
outline proposal was accepted
The project has changed since the outline application in the following ways:
1. Gloucestershire continued to be the pilot for the GP2DRS pilot during the early phases of this project
and MIQUEST extracts were used to compare data from GP systems with GP2DRS extracts.
Unfortunately, further delays in the GP2DRS implementation meant that we had to use MIQUEST
extractions to complete data extractions from other clinical partner areas working with us in
this project.
2. Unfortunately, the Coventry and Warwickshire programme withdrew from the project in August 2013.
This was as a result of unforeseen competing work pressures at their clinical site, unrelated to this
project. Effectively, the central team received no data from this site prior to their withdrawal from the
project, nor were there any project funds transferred to them.
3. In December 2013, the Health Technology Assessment programme approved Nottinghamshire replacing
Coventry and Warwickshire as the third site in the project in order to obtain data from ethnic minority
populations. The Nottingham Diabetic Retinopathy Screening service serves 28,000 people with diabetes:
12,000 patients in Nottingham City primary care trust (PCT) [ethnic mix: 4.7% black; 8.0% Asian; 4.3% DM)
and 16,000 patients in the southern half of the Nottinghamshire County PCT (ethnic mix: 1.0% black; 2.1%
Asian; 4.6% DM). Approval was received to transfer funding from the Coventry and Warwickshire allocation
to Nottinghamshire, to support their collection and supply of additional data from further GP practices.
4. A no-cost incorporation of data from a new clinical site in the East of England provided us with data
from approximately 70,000 (predominantly Caucasian) patients. This was provided by Health
Intelligence Ltd, the company running the screening services in the East of England. Acceptance and
incorporation of these data was approved by the HTA.
5. In February 2014, a no-cost time extension of 6 months for the project was approved by the HTA
programme, to support continued data collection and analyses, with a revised end date of November 2014.
6. The HTA Commissioning Board asked to see further clarification and justification for the randomised
splitting of the database that was in our original proposal and stated at the time of our application that
the Board felt it would probably be more useful to split the database in a systematic way. Hence, we
altered the method of splitting the database to a systematic method using the postcode of the GP to
define two areas (Group A and Group B) using the population data from the Office for National
Statistics for Local Government Districts. Group A includes the two more urban larger towns (Gloucester
and Cheltenham) and the remaining areas that make up Group A and Group B are more rural.
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Timeline changes
l Phase 1: Gloucestershire risk factor approach analysis commenced on 1 May 2012 and completed on
31 October 2012 as planned (Figure 1).
l Phase 2: extension to an ethnically diverse population commenced on 1 July 2012 in South London and
the first data sets were received in May 2013 and further data sets received until 1 April 2014.
Coventry and Warwickshire withdrew in August 2013.
The first DR screening data sets were successfully received from Nottinghamshire in August 2013 and
further data sets were received until 1 April 2014.
Analysis continued until mid-November 2014.
l Phase 3: the Oxford monitoring interval approach commenced on 1 November 2012 and was
completed on 27 April 2013.
l Phase 4: the health economic modelling commenced on 1 July 2012 and continued until
mid-November 2014.
Data sets
Gloucestershire 
data set extraction
Phase 1 Phase 2 Phase 3 Phase 4
Develop risk factor
models
Health economic
analysis
Project
write-up
Warwick UK
Asian
data set
extraction
South London
data set
extraction
Validation and
modification of
multivariate and
monitoring models to
account for ethnicity
Monitoring interval
approach to monitoring
Multivariate modelling to
derive risk score
Project write-up 
and dissemination
Incorporate
multivariate
and
monitoring
models in
health
economic
analysis
1 May 2012–
1 November 2012
1 November 2012–
1 May 2013
1 May 2012–
1 March 2014
1 July 2012–
30 June 2014
1 July 2014–
30 November 2014
FIGURE 1 Screening intervals for DR original study design.
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Chapter 3 On-going literature review conducted
by the research team
The review of the literature relating to screening for DR has been ongoing by the first author (PHS) sinceMarch 2000. The methodology involves a search technique for articles relating to screening or management
of DR utilising Zetoc, a co-operative venture between The British Library, Manchester Information and Associated
Services (MIMAS) and the Joint Information Systems Committee (JISC) of the UK Higher Education Funding
Council (see http://zetoc.mimas.ac.uk), which is available to universities; PHS has access through the University of
Oxford. Zetoc provides access to over 29,000 journals and more than 52 million article citations and conference
papers through The British Library ’s electronic table of contents. The database covers 1993 to the present day
and is updated daily.
The following subject, title and keywords were used:
‘retinopathy’, ‘digital’ and ‘imaging’ and ‘eye’, ‘digital’ and ‘imaging’ and ‘ophthalm’, ‘digital’ and
‘imaging’ and ‘diabet’, ‘laser’ and ‘eye’, ‘laser’ and ‘ophthalm’, ‘laser’ and ‘diabet’, ‘visual’ and ‘acuity’,
‘visual’ and ‘impairment’, ‘blindness’ and ‘diabet’, ‘diabetic’ and ‘screening’, ‘uptake’ and ‘screening’ and
‘diabet’ in title, ‘attendance’ and ‘screening’ and ‘diabet’, and/or ‘vitrectomy’ and ‘diabet’ in title.
These keywords were taken from other reviews in this area and refined to be selective to the field of
interest of the first author (screening or management of DR). In addition, the contents page lists of the
following journals, considered to be those most likely to publish articles relevant to this topic, were
reviewed each month:
Acta Ophthalmologica Scandinavia, American Journal of Ophthalmology, Archives of Ophthalmology,
British Journal of Ophthalmology, British Medical Journal, Clinical and Experimental Ophthalmology,
Current Eye Research, Diabetes, Diabetes Care, Diabetes Metabolism Research and Reviews, Diabetes
Research and Clinical Practice, Diabetes Technology and Therapeutics, Diabetic Medicine, Diabetologia,
European Journal of Ophthalmology, Eye, Graefes Archive for Clinical and Experimental Ophthalmology,
Investigative Ophthalmology and Visual Science, Journal of Diabetes and its Complications, Journal of
Medical Screening, Journal of the Eye, The Lancet, Ophthalmic Surgery and Lasers, Ophthalmologica,
Ophthalmology, Pediatric Diabetes, Retina and Survey of Ophthalmology.
Articles of interest identified with this search strategy were sourced from the local NHS host trust library or
online from the electronic journal resource (Athens51) accessible in the host trust library.
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Chapter 4 Added value: relevant work conducted
by members of the research team prior to
commencement of or during work on this Health
Technology Assessment project
The following work from members of the research team has helped to inform this project:
1. The GP2DRS project.52 Gloucestershire was the Phase 1 pilot site for the GP2DRS project. This project is
the primary phase of the GP2DRS programme, the objective of which is to automate the transfer of
relevant patient information between GP practices and NHS DR screening programmes. For the GP2DRS
Phase 1 pilot in Gloucestershire, 14,919 patients from 54 GP practices were identified on 17 April 2009
as being within the criteria [C10 coded (read code: diabetes) and 12 years old or over] for DR screening.
Within this group, 712 patients were not known to the Gloucestershire DESP. A detailed investigation
was carried out into the reasons why these patients were not known to Gloucestershire DESP.52
2. Over the subsequent 12 months, we sent out patient information leaflets to practices in
Gloucestershire, and we obtained risk factor data by September 2010 on 4220 people with diabetes by
means of a single letter sent after screening at a practice asking that practice to provide a consent code
update. Irene Stratton undertook a preliminary analysis33 of these data to check that they were of
sufficient quality for this grant proposal. Irene Stratton also analysed all the outputs from the Electronic
Annual Reporting System for the 91 eye screening programmes in England, in order to try and improve
data quality. A full-time administrator was appointed in January 2011 in Gloucestershire in order to
communicate with GP practices to encourage them to update the consent codes during 2011 so that
we could achieve our target of 15,000 people with both historic risk factor and retinopathy screening
data by the end of 2011.
3. The risk factor data that were collected from transfer of data from GP systems in the GP2DRS data
transfer or via MIQUEST extractions included age, sex, ethnicity, duration of diabetes, diabetes type,
visual acuity, certified severely sight impaired or blind, certified sight impaired or partially sighted, body
mass index (BMI), systolic blood pressure, diastolic blood pressure, HbA1c, serum creatinine.
4. Our research group developed a simple risk stratification model for time to development of STDR,39
which was based on categorising the digital photographic screening results from two consecutive
annual digital photographic screenings.
5. Our research group also published a paper demonstrating the influence of background DR in the
second eye on rates of progression of DR in our cohort of patients in Gloucestershire between 2005
and 2010.53
6. IS was one of a team of researchers who were involved in a research report produced by the University
of Warwick on behalf of the Four Nations Diabetic Retinopathy Study Group entitled ‘Rapid literature
review: would changing diabetic eye screening intervals from the current annual recommendation lead
to changed clinical outcomes?’54
7. There has been much debate over the years on the influence of one or both eyes on quality-of-life
scores and, believing that work in this area would be useful for this HTA project, we undertook a
retrospective analysis of data collected in 289 people with diabetic macular oedema at baseline in a
randomised clinical trial with diabetic macular oedema, and we recommended that a weighted visual
acuity measure from both eyes is considered in future diabetic macular oedema trials.55
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8. We studied the agreement between screening photographic and hospital biomicroscopy grading of DR
in two separate published audits56,57 which has helped to inform Phase 3 of this project – the
monitoring interval approach (see Chapter 7).
9. Measurement of severely sight impaired or blindness rates in Gloucestershire. Gloucestershire has had a
DESP based on two-field digital photography since 1998 and the numbers of people registered sight
impaired (previously termed ‘partially sighted’) and severely sight impaired (previously termed ‘blind’)
are very low. Please note that this uses the UK definitions and not the World Health Organization
definitions (see Glossary).
The numbers of people recorded as sight impaired and severely sight impaired in the last few years are
shown in Table 1.
The previously reported58 lowest annual incidence of blindness was reported in Newcastle as having been
reduced to 0.035% of the population with diabetes.
TABLE 1 Severe sight impairment or blindness in Gloucestershire
Years
Annual incidence
numbers registered
severely sight
impaired or blind
Percentage of the
population with diabetes
registered severely sight
impaired or blind
Annual incidence
numbers registered
sight impaired or
partially sighted
Percentage of the
population with diabetes
registered sight impaired
or partially sighted
2005–8 5.33 per annum 0.024% 8.7 per annum 0.039%
2010–13 1 per annum 0.0034% 4.3 per annum 0.015%
WORK CONDUCTED PRIOR TO COMMENCEMENT/DURING WORK ON THIS HTA PROJECT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
12
Chapter 5 Phase 1: risk factor approach
Rationale
Rates of incidence and progression of retinopathy are greater in people with a longer duration of diabetes
and with poor glycaemic control (higher HbA1c) and may also vary with other factors such as blood
pressure and diabetes type. It has been shown in Denmark that it is possible to identify those at higher
absolute risk of STDR,59 and this suggests that it may be possible to identify subgroups of those with
diabetes in whom the screening interval can be extended without risk of STDR developing before the next
screening visit. This Danish model was constructed using published data from several clinical trials for
which patients were recruited in the 1970s and 1980s and followed into the 1990s. The Danish model
may not be optimal for patients diagnosed in the past decade as these patients tend to be more obese
and to be diagnosed somewhat earlier in the disease process as opportunistic screening becomes
more frequent.
Data set
The Gloucestershire Diabetic Eye Screening Programme (GDESP) includes 27,000 people aged 12 years or
older with diabetes who are eligible for annual screening. Our database includes:
l longitudinal data on photographs from 2005 to the present
¢ digital photographs on two fields, with mydriasis (eyes dilated) to maximise image quality
¢ consistent grading team
¢ quality control, including repeat grading and external quality assurance
¢ patients invited for screening annually but may attend less frequently
l risk factor data through separately funded ‘GP2DRS’ project
¢ risk factor data were available from GP electronic records (EMIS) on 4400 screened patients by
September 2010
¢ by the end of December 2011, we had received risk factor data on over 12,000 patients.
Given that this data set is much larger than needed for this project, we used a data-splitting approach.
We had originally planned to randomly select 50% of patients for the model derivation data set (‘derivation
data’) and to reserve the other 50% for model validation purposes (‘validation data’). However, the
reviewers on our original application suggested that a non-random method might be used for constructing
the samples for the risk model and then testing it. We therefore altered the method of splitting the
database to a systematic method using the postcode of the GP to define two areas (Group A and Group B)
with similar sized populations using the population data from the Office for National Statistics for Local
Government Districts (Table 2). Group A includes three more urban larger towns (Gloucester, Tewkesbury
and Cheltenham) and the remaining areas that make up Group B are more rural.
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Methods
Exploratory data analysis was used to look for outliers in all variables. The population was divided into
derivation and validation sets based on the postcode of the GP practice. Screening data were used from
2005, the date at which retinal cameras were upgraded to modern camera backs and grading was stable.
For each SE, the most recent clinical data items were identified and the baseline SE was defined as the first
at which all required variables were present. Patients were included in the cohort if they had one of three
categories of DR at initial eye screening: no DR in either eye; mild DR in only one eye; or mild DR in both
eyes. Cox proportional hazard models were used with interval censoring to identify risk factors for
progression. The parameter estimates from the derivation set were applied to the patients within the
validation set and the risk of progression to referable DR is reported by centile of risk. In those patients
with at least three SEs and clinical variables at the second of these visits we compared this model with our
previously published risk model.39
The multivariate modelling used the following parameters:
l outcome (either of):
¢ referable DR (grade R2 pre-proliferative or R3 proliferative)
¢ referable diabetic maculopathy (grade M1)
l exposures:
¢ age, sex, smoking, BMI
¢ previous retinal photographs
¢ duration of diagnosed diabetes
¢ type of diabetes
¢ HbA1c
¢ systolic and diastolic blood pressure
¢ measurements of renal function (urine albumin, serum creatinine)
¢ lipid measurements
l analysis:
¢ Cox proportional hazards model with interval-censoring (as retinopathy status can only be observed
at screening visits not at the point at which STDR actually develops)
¢ stepwise selection was used to develop a risk score for referable retinopathy/maculopathy at
subsequent visits.
TABLE 2 The population data from the Office for National Statistics for Local Government
Derivation and validation set District Council areas of Gloucestershire Population Total
Group A Gloucester 117,300
Cheltenham 113,900
Tewkesbury 80,600
Subtotal 311, 800
Group B Cotswolds 83,500
Forest of Dean 82,800
Stroud 111,100
Subtotal 277,400
Total 589,200
PHASE 1: RISK FACTOR APPROACH
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We also developed a model for risk of progression to maculopathy alone and the risk of progression to
pre-proliferative DR and PDR alone.
Results
In total, 84,148 screening events were available, of which 75,491 were in 2005 or later. However, grading
results were stored separately and once matching was carried out, and those with missing grading results
omitted, there were 72,077 episodes and, of these, 15,410 had two or more SEs.
The data extraction from the GP practices yielded 3.3 million data items. Results recorded within the data
set are shown in Tables 3 and 4.
In exploratory analyses, models were fitted using all variables from Table 3, but urine albumin was
subsequently dropped as the data were not available for all patients, and its inclusion led to the overall loss
of 12% of data from patients and 20% of the follow-up time.
The grading levels recorded by the programme are the same as those recorded in the NHS DESP in
England and are shown in Table 5 with an approximate Early Treatment Diabetic Retinopathy Study
(ETDRS) grade.
TABLE 3 Recording of results within the data set
Clinical and biochemical
measures n Median
25–75th
centile
Minimum,
maximum
Median
observations
per patient
HbA1c (mmol/mol) 311,405 55 46 to 66 20, 199 16
BMI (kg/m2) 277,858 30.3 26.8 to 34.7 15.1, 69.9 11
Diastolic blood pressure (mmHg) 523,712 80 72 to 88 30, 210 20
Systolic blood pressure (mmHg) 525,517 140 130 to 153 50, 290 20
Serum creatinine (µmol/l) 285,914 84 72 to 101 2.8, 1484 12
Total cholesterol (mmol/l) 217,405 4.5 3.8 to 5.4 0.4, 20.0 10
Urine albumin/ creatinine ratio
(mg/mmol)
89,984 0.9 0.5 to 2.6 0.0, 791.2 5
TABLE 4 Recording of smoking results within the data set
Smoking status (n= 233,149)
Median observations per patientCurrent smoker Ex-smoker Never smoked Unknown
45,200 101,152 86,766 31 10
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The model fitting was explored using patients for whom age, duration of diabetes, blood pressure, HbA1c,
glomerular filtration rate, smoking status, diabetes type and BMI were available. In total, 7012 people with
diabetes were included in the derivation set and 5778 people with diabetes were included in the validation
set (Table 6).
We investigated the effect of clinical variables having adjusted for the number of eyes with mild,
non-proliferative DR (NPDR) to look at the univariate effects (Table 7).
The results (Table 8) of the Cox proportional hazards model show that the presence of background DR in
both eyes at a screening visit has the highest hazard ratio (HR) of 7.13 [95% confidence interval (CI 5.84
to 8.70)] with background DR in one eye having a HR of 2.56 (95% CI 2.05 to 3.20), and HbA1c of 1.28
(95% CI 1.23 to 1.34), and duration of diabetes (per 5 year increase), total serum cholesterol (per 1mmol/l)
and serum creatinine (per 10 µmol/l) all having lower HRs.
Hence, the risk score for a patient with mild NPDR in both eyes is given by:
1:96þ (0:25 (HbA1c=10))þ (0:18 duration of diabetes=5))þ (0:11 total cholesterol)
þ (0:04 serum creatinine=10) (1)
The risk score for a patient with mild NPDR in one eye is given by:
0:94þ (0:25 (HbA1c=10))þ (0:18 (duration of diabetes=5))þ (0:11 total cholesterol)
þ (0:04 serum creatinine=10) (2)
The risk score for a patient with no retinopathy is given by:
(0:25 (HbA1c=10))þ (0:18 (duration of diabetes=5))þ (0:11 total cholesterol)
þ (0:04 serum creatinine=10) (3)
TABLE 5 Grading levels of the English NHS DESP
NHS DESP category
Approximate ETDRS
equivalent(s) Description/features
R0M0 10 No detected DR
R1 14 to 35 Background DR (mild NPDR): microaneurysm(s) and/or retinal
haemorrhage, with or without exudate or cotton wool spots
R2 43 to 53 Pre-proliferative (moderate to severe NPDR): multiple deep, round or blot
haemorrhages and/or definite IRMA and/or venous beading and/
or reduplication
R3 61 and greater PDR: any new vessels, pre-retinal fibrosis, vitreous or pre-retinal
haemorrhage with or without tractional detachment
M0 No direct equivalent Absence of any M1 features below
M1 (with any of R1,
R2 or R3)
No direct equivalent Maculopathy (presence of any two-dimensional photographic markers of
diabetic maculopathy):
l exudate within 1-disc diameter of the centre of the fovea
l circinate or group of exudates within the macula
l microaneurysm or haemorrhage within 1-disc diameter of the centre
of the fovea, but only if associated with a best visual acuity of 0.3
logMAR or worse (equivalent to Snellen 6/12)
ETDRS, Early Treatment Diabetic Retinopathy Study; logMAR, logarithm of the minimum angle of resolution; IRMA, intraretinal
microvascular abnormality; NPDR, non-proliferative DR.
PHASE 1: RISK FACTOR APPROACH
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TABLE 6 Characteristics of the derivation and validation sets
Risk factors
Derivation set Validation set
p-value for differencen= 7012 n= 5778
Progressed to STDR events, n (%) 606 (8.5) 490 (8.5) 0.74
Sex, n (%)
Male 3932 (56.1) 3328 (57.6) 0.08
Female 3080 (43.9) 2450 (42.4)
Diabetes type, n (%)
Type 1 305 (4.4) 296 (5.1) 0.08
Type 2 6707 (95.6) 5482 (94.9)
Ever smoked, n (%)
No 3438 (49.0) 2681 (46.4) 0.003
Yes 3574 (51.0) 3097 (53.6)
Current smoker, n (%)
No 6098 (87.0) 5085 (88.0) 0.077
Yes 914 (13.0) 693 (12.0)
DR status, n (%)
No DR 4638 (66.1) 3698 (64.0) 0.017
One eye mild NPDR 1411 (20.1) 1231 (21.3)
Two eyes mild NPDR 963 (13.7) 849 (14.7)
HbA1c (mol/mol), n (25–75th centile) 50 (43 to 60) 50 (43 to 60) 0.06
Total serum cholesterol, n (25–75th centile) 4.3 (3.7 to 5.1) 4.3 (3.7 to 5.0) 0.51
Glomerular filtration rate, n (25–75th centile) 78 (66 to 91) 78 (65 to 91) 0.13
Years since diagnosis of diabetes,
n (25–75th centile)
1.9 (0.6 to 5.9) 2.2 (0.8 to 6.1) < 0.0001
Age at baseline screening (years),
n (25–75th centile)
65 (55 to 73) 65 (57 to 72) 0.025
Systolic blood pressure, n (25–75th centile) 134 (125 to 142) 135 (127 to 142) 0.0034
Diastolic blood pressure, n (25–75th centile) 79 (70 to 82) 78 (70 to 82) < 0.0001
BMI (kg/m2), n (25–75th centile) 29.9 (26.5 to 33.9) 29.9 (26.7 to 33.8) 0.484
NPDR, non-proliferative DR.
p-values from Wilcoxon rank-sum test or chi-squared test as appropriate.
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TABLE 8 Results of Cox proportional hazards model time to STDR (R2, R3 or M1)
Risk factors Parameter estimate HR 95% CI
Background DR (mild NPDR) in both eyes at screening visit 1.96 7.1 5.8 to 8.7
HbA1c (per 10mmol/mol increase) 0.25 1.28 1.23 to 1.34
Duration of diabetes (per 5 year increase) 0.18 1.20 1.16 to 1.24
Background DR (mild NPDR) in one eye at screening visit 0.94 2.6 2.0 to 3.2
Total serum cholesterol (per 1mmol/l) 0.11 1.12 1.05 to 1.19
Serum creatinine (per 10 µmol/l) 0.004 1.04 1.01 to 1.07
TABLE 7 Hazard ratios and 95% confidence intervals for progression after fitting number of eyes with mild NPDR
(unadjusted for HbA1c or duration of diabetes) and explanatory information which links type of diabetes to
duration and HbA1c
HR for progression to
STDR (95% CI)
HR for progression to
maculopathy (95% CI)
HR for progression to
R2 or R3 (95% CI)
Systolic blood pressure (per 10mmHg) 1.03 (0.98 to 1.08) 1.01 (0.96 to 1.07) 1.08 (1.01 to 1.17)
Diastolic blood pressure (per 10mmHg) 0.95 (0.87 to 1.03) 0.95 (0.86 to 1.03) 1.00 (0.88 to 1.14)
Type 2 vs. type 1 diabetes 0.45 (0.38 to 0.58) 0.54 (0.42 to 0.68) 0.39 (0.29 to 0.53)
Smoking status
Ever smoked 0.89 (0.75 to 1.05) 0.94 (0.78 to 1.12) 0.90 (0.69 to 1.19)
Current smoker 0.99 (0.76 to 1.3) 0.94 (0.70 to 1.25) 1.16 (0.77 to 1.74)
Sex: female 1.10 (0.95 to 1.28) 1.16 (0.96 to 1.36) 1.06 (0.83 to 1.36)
HbA1c (per 10mmol/mol) 1.31 (1.26 to 1.36) 1.29 (1.24 to 1.35) 1.47 (1.39 to 1.55)
Duration of diabetes (per 5 years) 1.20 (1.17 to 1.24) 1.18 (1.13 to 1.22) 1.26 (1.20 to 1.32)
BMI (kg/m2) 0.99 (0.98 to 1.01) 0.99 (0.98 to 1.01) 1.01 (0.99 to 1.03)
Serum creatinine (per 10 µmol/l) 1.02 (0.99 to 1.05) 1.02 (0.99 to 1.06) 1.00 (0.94 to 1.05)
Total cholesterol (mmol/l) 1.14 (1.07 to 1.22) 1.16 (1.01 to 1.25) 1.15 (1.03 to 1.28)
Urine albumin 1.01 (1.00 to 1.015) 1.01 (1.00 to 1.020) 1.01 (1.006 to 1.02)
Explanatory information which links type of diabetes to diabetes duration and HbA1c
Type 1 diabetes Type 2 diabetes
HbA1c (mmol/mol) 64 (55 to 76) 50 (43 to 60)
Duration of diabetes 17 (8 to 28) 2.0 (0.7 to 5.7)
CI, confidence interval; HR, hazard ratio.
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The model was built using these risk factors. The ROC curve for overall endpoints in the validation set is
shown in Figure 2.
Estimates of the ROC curve at given time points were obtained using the SAS macro TDROC (time dependent
receiver operating characteristic) written by Mithat Gönen of Memorial Sloan Kettring Cancer Centre60 which
generates a time-dependent ROC curve at a given time point for a censored outcome and an ordinal or
continuous predictor. CIs were obtained using boot-strapping. Figure 3 shows the Kaplan–Meier estimates
of time to referral by quintile of risk in the validation data set. At 4 years, 25% of those in the top quintile
have been referred and in the lowest quintile fewer than 2% have been referred.
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FIGURE 2 Receiver operating characteristic curve for validation data set. AUC, area under the curve.
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FIGURE 3 Validation data set: time to referable screening result by quintile of risk (i.e. Group 1 contains those
whose risk score is 0–20th centile, Group 2 is 21–40th centile, Group 3 is 41–60th centile, Group 4 is 61–80th centile,
Group 5 is 81–100th centile).
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The characteristics that are included in the model of the highest and lowest risk groups in the validation
set are shown in Table 9.
The characteristics that are not included in the model of the highest and lowest risk groups in the
validation set are shown in Table 10. There is very little difference in systolic and diastolic blood pressure
between the highest and lowest risk groups in the validation set. Better control of blood pressure in the
current era is likely to be the reason why blood pressure does not influence the model.
Figure 4 shows that almost all of the PDR is detected in the highest quintile of risk. The data are also
shown in Table 11, which shows that no PDR is detected in the lowest two deciles of risk. The progression
to STDR is shown in Table 12.
The risk estimates are demonstrated in Figure 5.
Although the aim of the project was to examine the risk of progression to STDR for maculopathy M1 or
for retinopathy (R2 or R3) collectively, we have examined the model fit for these endpoints separately.
TABLE 9 Characteristics of highest and lowest risk groups in validation data set that are included in the risk model
Data items in risk model Lowest quintile (n= 1071) Highest quintile (n= 1195)
Mild NPDR at previous SE
Neither eye, n (%) 1071 (100) 53 (4.4)
One eye, n (%) 0 (0) 295 (24.7)
Both eyes, n (%) 0 (0) 847 (70.88)
HbA1c, mmol/mol (IQR) 42 (39–44) 58 (49–72)
Duration diabetes at baseline screen, years (IQR) 0.9 (0.5–1.75) 6.2 (1.3–13.25)
Serum total cholesterol, mmol/l (IQR) 4.0 (3.5–4.6) 4.3 (3.7–5.1)
Serum creatinine, µmol/l (IQR) 78 (67–91) 84 (72–100)
IQR, interquartile range.
TABLE 10 Characteristics of highest and lowest risk groups in validation data set that are not included in the
risk model
Data items not in risk model Lowest quintile (n= 1071) Highest quintile (n= 1195)
Sex, n (%)
Male 563 (52.6) 726 (60.8)
Female 508 (47.4) 469 (39.2)
Type of diabetes, n (%)
Type 1 DM 6 (0.56) 183 (15.3)
Type 2 DM 1065 (99.4) 1012 (84.7)
Age at first screen, years (IQR) 66 (58–73) 64 (55–71)
Systolic blood pressure, mmHG (IQR) 134 (125–140) 136 (127–144)
Diastolic blood pressure, mmHG (IQR) 76 (70–80) 77 (70–82)
PHASE 1: RISK FACTOR APPROACH
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FIGURE 4 First referable retinopathy detected by decile of risk in validation set.
TABLE 11 First referable retinopathy detected by decile of risk in validation set
Decile No referable DR R1M1 R2M0 R2M1 R3M0 R3M1
1 542 7 0 1 0 0
2 559 8 1 0 0 0
3 555 20 1 0 1 1
4 583 21 0 0 1 0
5 587 21 1 1 0 0
6 563 28 5 0 1 0
7 578 24 2 3 0 0
8 551 36 11 6 0 0
9 530 70 12 4 2 0
10 376 123 67 35 9 0
TABLE 12 Event rate in validation set: rate of progression to STDR
Risk quintile Number in risk group Number of events
Rate of progression to
STDR (per 1000 PYs)
Exposure
time (PYs)
1 1092 19 4.8 47,707
2 1190 42 9.1 55,690
3 1218 52 10.0 62,459
4 1218 88 18.4 57,404
5 1232 325 74.8 52,125
PY, person-year.
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FIGURE 5 Model fitting for risk of progression to STDR. (a) No DR, HR compared with patient with no DR, 5 years
of diabetes, HbA1c= 50mmol/mol; (b) mild NPDR in one eye, HR compared with patient with no DR, 5 years of
diabetes, HbA1c= 50mmol/mol; and (c) mild NPDR in both eyes, HR compared with patient with no DR, 5 years
of diabetes, HbA1c= 50mmol/mol.
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These analyses (Tables 13 and 14) show that for progression to retinopathy R2 or R3, the presence of
background retinopathy in both eyes or in just one eye is a more important risk factor than in progression
to maculopathy M1. Cholesterol does not enter the model for progression to R2 or R3 but systolic blood
pressure does enter the model. The inclusion of systolic blood pressure in the model of progression to
R2 or R3 reflects results from earlier studies which analysed the progression of retinopathy alone
(not including maculopathy) using scales such as the ETDRS scale.
Further analyses were carried out to assess the performance of the model proposed in our earlier paper
based on the outcomes of two consecutive SEs.39
The derivation data set for these analyses consisted of those patients who had two SEs with no referable
DR and at least one further SE.
We looked at the performance of three models:
l two baseline SEs and clinical risk factor (CRF) data
l two baseline SEs
l one SE and CRF data.
In the Tables 15a–15c we have calculated the parameter estimates and HRs for the different models in all
patients who had at least three SEs and clinical data available. In the derivation set, there were 162 events
in 5774 people, and in the validation set, there were 131 events in 4873 people.
The following figures (Figures 6 and 7) show progression to referable DR by risk group. It is not possible to
use quintiles of risk because most of the patients are in the low-risk group (no DR in each of two SEs).
Hence, the groups have been defined to have the same number of patients as in the two SEs model.
TABLE 14 Risk factors for progression to retinopathy R2 or R3
Risk factors Parameter estimate HR 95% CI
Background DR (mild NPDR) in both eyes at screening visit 2.6 14.1 10 to 21
HbA1c (per 10mmol/mol increase) 0.39 1.5 1.4 to 1.6
Duration of diabetes (per 5 year increase) 0.24 1.27 1.21 to 1.33
Background DR (mild NPDR) in one eye at screening visit 1.2 3.4 2.2 to 5.5
Systolic blood pressure 0.09 1.09 1.01 to 1.17
TABLE 13 Risk factors for progression to maculopathy M1
Risk factors Parameter estimate HR 95% CI
Background DR (mild NPDR) in both eyes at screening visit 1.81 6.1 4.9 to 7.5
HbA1c (per 10mmol/mol increase) 0.22 1.25 1.20 to 1.31
Duration of diabetes (per 5 year increase) 0.17 1.18 1.13 to 1.23
Background DR (mild NPDR) in one eye at screening visit 0.88 2.4 1.9 to 3.0
Total serum cholesterol (per 1mmol/l) 0.13 1.14 1.06 to 1.22
Serum creatinine (per 10 µmol/l) 0.05 1.05 1.01 to 1.08
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TABLE 15A Parameter estimates and HRs for the model with two screens plus clinical data
Retinopathy status and clinical
variables at first screen’
Retinopathy status and clinical
variables at second screen’
Clinical data and
two screens
Clinical data and
two screens
Parameter estimate HR (95% CI)
First background two eyes Second background two eyes 2.7 13.8 (10.6 to 18.1)
First background one eye Second background two eyes 2.0 7.4 (5.2 to 10.7)
First no DR Second background two eyes 1.5 4.5 (3.1 to 6.5)
First background two eyes Second background one eye 1.1 3.1 (1.6 to 6.0)
First background one eye Second background one eye 1.3 3.6 (2.4 to 5.4)
First no DR Second background one eye 1.0 2.8 (2.0 to 3.0)
First background two eyes Second no DR Not in model Not in model
First background one eye Second no DR Not in model Not in model
First no DR Second no DR Reference Reference
HbA1c (per 10mmol/mol) 0.3 1.35 (1.29 to 1.42)
Total cholesterol 0.16 1.17 (1.06 to 1.3)
TABLE 15C Parameter estimates and HRs for the model with one SE plus CRF data
Retinopathy status and clinical
variables at first screen Clinical data and one screen Clinical data and one screen
Parameter estimate HR (95% CI)
Both eyes with background DR 2.1 8.1 (6.2 to 10.4)
HbA1c 0.3 1.34 (1.27 to 1.42)
One eye with background DR 1.1 3.0 (2.2 to 4.0)
Duration of diabetes per 5 years 0.10 1.11 (1.05 to 1.17)
Total cholesterol 0.16 1.12 (1.06 to 1.30)
TABLE 15B Parameter estimates and HRs for the model with two SEs only
Retinopathy status at
first screen
Retinopathy status at
second screen’ Two screens Two screens
Parameter estimate HR (95% CI)
First background two eyes Second background two eyes 2.8 16.7 (12.8 to 21.8)
First background one eye Second background two eyes 2.1 8.1 (5.7 to 11.6)
First no DR Second background two eyes 1.6 4.8 (3.3 to 6.9)
First background two eyes Second background one eye 1.17 3.2 (1.7 to 6.2)
First background one eye Second background one eye 1.25 3.5 (2.3 to 5.2)
First no DR Second background one eye 1.12 3.1 (2.2 to 4.3)
First background two eyes Second no DR Not in model 1
First background one eye Second no DR Not in model 1
First no DR Second no DR Reference 1
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FIGURE 6 Progression to referable STDR by risk group in the three models. (a) Risk stratification in validation set
using results of two SEs and clinical data; (b) risk stratification in validation set using results of two SEs; and (c) risk
stratification in validation set using one SE and clinical information.
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FIGURE 7 The proportion of each grade of retinopathy by risk group in those found with referable retinopathy at
the first SE where it was detected. (a) Referable retinopathy found by risk group: two screens plus clinical data;
(b) referable retinopathy found by risk group: two screens; and (c) referable retinopathy found by risk group:
one screen plus clinical data.
PHASE 1: RISK FACTOR APPROACH
NIHR Journals Library www.journalslibrary.nihr.ac.uk
26
The bar charts in Figures 6 and 7 show the proportion of each grade of retinopathy by risk group in those
found with referable retinopathy at the first SE where it was detected. There is no significant difference in
the proportion of each grade of retinopathy between the three models.
Figure 8 and Table 16 show very little difference in the area under the curve (AUC) of the ROCs between
the three models.
The AUC and 95% CI from boot-strapping are shown in Table 16.
Does the inclusion of cholesterol into the model improve
the fit?
Although the addition of variables into the model may improve the fit using conventional estimations of
fit, these may have little impact when it comes to defining groups for allocation of screening intervals.
In order to examine this we have fitted the model including and excluding total cholesterol.
The distribution of risk for those who go on to develop STDR and those who do not develop STDR in the
validation sets is shown in Figure 9.
Reclassification among people who progressed to STDR and those who did not during follow-up is shown
in Tables 17a–17d.
We now sum groups 1 to 3 because these groups have very similar progression rates to STDR.
Reclassifications for subjects with and without events are summarised below.
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FIGURE 8 Model comparison.
TABLE 16 AUC and 95% CI of the three models
Model AUC 95% CI
Two SEs plus clinical data 0.786 0.759 to 0.813
Two SEs 0.759 0.732 to 0.788
One SE plus clinical data 0.774 0.748 to 0.800
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TABLE 17A Patients who progressed to STDR with groups 1–3 separated. Light green shading indicates those who
move into a higher group when cholesterol is added to the model and dark green shading indicates those who
move into a lower group
Quintile of risk with cholesterol in the model
Quintile of risk without
cholesterol in the model
1 2 3 4 5 Total
1 18 5 0 0 0 23
2 5 34 2 0 0 41
3 0 3 46 3 0 52
4 0 0 8 79 2 89
5 0 0 0 3 318 321
Total 23 42 56 85 320 526
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FIGURE 9 Ranked centile of linear risk predictor for those with and without STDR. Centile rank with cholesterol vs.
centile rank without cholesterol. (a) With STDR; and (b) without STDR.
TABLE 17B Patients who did not progress with groups 1 to 3 separated. Light green shading indicates those who
move into a higher group when cholesterol is added to the model and dark green shading indicates those who
move into a lower group
Quintile of risk with cholesterol in the model
Quintile of risk without
cholesterol in the model
1 2 3 4 5 Total
1 991 176 0 0 0 1167
2 170 853 126 0 0 1149
3 6 118 930 84 0 1138
4 0 1 78 990 32 1101
5 0 0 0 31 838 869
Total 1167 1148 1137 1105 870 5424
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When cholesterol is added to the model, those whose ranking does not change remain on the diagonal,
those who move into a higher group are in shaded light green and those who move into a lower group
are shaded dark green.
The net gain in reclassification proportion can be shown using the reclassification methods of
Pencina et al.61
For 12 subjects who progressed to STDR, classification improved using the model with high-density
lipoprotein, and for 19 people it became worse. This may be estimated using formulae of Pencina et al.61
with the net gain in reclassification proportion of 0.120, significantly greater than zero (p-value< 0.001).
The net gain in reclassification proportion for subjects who did not experience an event was not significant;
174 individuals were reclassified down and 173 were reclassified up (p-value= 0.957). The net reclassification
improvement (NRI) was estimated at 0.121 and was highly significant (p-value< 0.001).
P(upjD =1) = p^up,events = #events moving up
#events
=
5
526
= 0:010 (4)
P(downjD =1) = p^down,events = #events moving down
#events
=
11
526
=0:021 (5)
P(upjD =0) = p^up,nonevents = #events moving up
#nonevents
=
116
5424
=0:021 (6)
P(downjD =0) = p^down,nonevents = #events moving down
#nonevents
=
110
5424
=0:020 (7)
TABLE 17D Patients who did not progress with groups 1 to 3 combined. Light green shading indicates those who
move into a higher group when cholesterol is added to the model and dark green shading indicates those
who move into a lower group
Quintile of risk with cholesterol in the model
Quintile of risk without
cholesterol in the model
1 to 3 4 5 Total
1 to 3 3370 84 0 3454
4 79 990 32 1101
5 0 31 838 869
Total 3449 1105 870 5424
TABLE 17C Patients who progressed to STDR with groups 1 to 3 combined. Light green shading indicates those
who move into a higher group when cholesterol is added to the model and dark green shading indicates
those who move into a lower group
Quintile of risk with cholesterol in the model
Quintile of risk without
cholesterol in the model
1 to 3 4 5 Total
1 to 3 113 3 0 116
4 8 79 2 89
5 0 3 318 321
Total 121 85 320 526
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The NRI is estimated as:
= (p^up,events − p^down,events) − (p^up,nonevents − p^down,nonevents)
= (0:010−0:021) − (0:021−0:020) =−0:011−0:001 =−0:010
Z =
est(NRI)ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
p^up,eventsþ p^down,events
#events
þ p^up,noneventsþ p^down,nonevents
#nonevents
r
=−0:010=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
0:010þ 0:021
526
þ 0:021þ 0:020
5424
r
=−0:010=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
0:00006þ 0:0000076
p
=−0:010=0:008
=−1:25
p-value =0:2113
(8)
Looking at the changes in those with events:
Zevents =
p^up,events − p^down,eventsﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
p^up,eventsþ p^down,events
#events
r = 0:010 − 0:021ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
0:010þ 0:021
526
r = −0:011ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
0:031
526
r = −0:011
0:0077
=1:43
P =0:1527
(9)
And in those without events:
Znonevents =
p^up,nonevents − p^down,noneventsﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
p^up,nonevents þ p^down,nonevents
#events
r = 0:021− 0:020ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
0:021þ 0:020
5424
r = 0:001ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
0:041
5424
r = 0:001
0:00275
=0:363
P =0:7188
(10)
So, the addition of cholesterol to the model does not improve net reclassification.
Classical risk factors for progression of diabetic retinopathy
The model used in this study was intended to determine the risk of referable DR, which included the risk of
developing maculopathy as well as the risk of development of pre-proliferative DR or PDR. Some classical
risk factors did not enter the model (e.g. blood pressure) because, although they were significant for the
development of pre-proliferative DR or PDR, blood pressure was not significant in the development of
maculopathy and so did not have a significant influence on the development of referable retinopathy.
A total of 68% of the referable events were for maculopathy. The overall blood pressure was also better
controlled than in the era of the UK Prospective Diabetes Study (UKPDS) study and the ETDRS study, and
patients who attend regularly for screening do have better control than those who do not.
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Chapter 6 Phase 2: extension to ethnically
diverse populations
Rationale
It is good practice to verify statistical modelling results in external data, especially given that the Gloucestershire
data are atypically high quality and collected on an ethnically homogenous population.62 In this project we
verified the results of Phase 1 modelling, described in Chapter 5, in external data sets of greater diversity.
Data
l Data from the East Anglian Programme including risk factors and grading results.
l Data from the South London screening service including risk factors and grading results.
l Data from the Nottingham screening service including risk factors and grading results.
We tested the risk score and algorithm against outcome retinopathy grades in the data sets.
Expected outcome
To develop a validated algorithm for recalling patients of white, Asian or African-Caribbean ethnicities for
retinopathy screening, for use by the NHS Diabetic Eye Screening Programme and the
84 individual screening programmes across England.
Potential limitations
The Gloucestershire programme has a well-established quality-assured screening service with a stable
group of experienced graders. Hence, it may not be typical of all screening programmes. Even with
controls in place, it is likely that some misgrading will have occurred. We have, therefore, estimated when
this may have occurred in Chapter 5 and utilised this in Chapter 7.
Gloucestershire has a small ethnic minority population. The main ethnic minority groups in Gloucestershire are
Indian/British Indian (0.7%), and black/black British (0.8%), although the percentage of people from an ethnic
minority group in the population with diabetes in Gloucestershire is nearer 5% because of the higher
prevalence of diabetes in these groups. East Anglia has a similar low prevalence of ethnic minority groups.
However, the data from South London and Nottingham used data sources that include a higher ethnic
minority population from UK Asian, African-Caribbean and other white (i.e. non-British) Caucasian groups.
Results
The minimal model includes the following parameters:
l mild NPDR in both eyes at screening visit, HR 6.98 (95% CI 5.75 to 8.47)
l mild NPDR in one eye at screening visit, HR 2.50 (95% CI 2.01 to 3.12)
l HbA1c (per 10mmol/mol increase), HR 1.30 (95% CI 1.25 to 1.35)
l duration of diabetes (per 5 year increase), HR 1.20 (95% CI 1.16 to 1.24).
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The model was validated in the following external data sets:
l data from 17,634 people with diabetes in the East Anglian Programme (A) who have grading results
from two SEs and risk factor data
l data from 1223 people with diabetes in the South London Screening Service (B) who have grading
results from two SEs and risk factor data
l data from 1083 people with diabetes in the Nottingham Screening Service (C) who have grading
results from two SEs and risk factor data.
Data from programmes A, B and C are shown in Table 18.
TABLE 18 Validation data sets
Programme A: n= 17,634 B: n= 1223 C: n= 1083
Sex (%)
Male 56 50 52
Female 44 50 47
Years since diagnosis of diabetes at
baseline screen (IQR)
4.5 (1.0–8.7) 3.5 (1.3–6.7) 2.9 (0.6–6.6)
Diabetes type (%)
Type 1 DM 5 5 7
Type 2 DM 95 95 93
Age at baseline screen, years (IQR) 66 (57–74) 59 (49–68) 61 (52–69)
HbA1c, IFCC mmol/mol (IQR) 55 (49–66) 52 (45–64) 53 (46–63)
HbA1c, DCCT % (IQR) 7.2 (6.6–8.2) 6.9 (6.3–8.0) 7.0 (6.4–7.9)
Total cholesterol, mmol/l (IQR) 4.3 (3.7–5.0) 4.6 (4.0–5.3) 4.4 (3.7–5.1)
First screen R0M0, n (%) 13,121 (74.4) 957 (78.3) 823 (76.0)
First screen R1M0 in one eye, n (%) 2372 (13.4) 165 (13.5) 141 (13.0)
First screen R1M0 in both eyes, n (%) 2141 (12.2) 101 (8.3) 119 (11.0)
Ethnicity (%)
Caucasian 98.0 46.9 81
African or African-Caribbean 0.4 31.4 18.5
Asian 1.0 11.3 1.5
Mixed 0.3 4.3 0
Other 0.3 5.9 0
Median follow-up, years (IQR) 2.7 (2.0–3.0) 3.8 (2.0–6.8) 4.2 (2.2–5.3)
DCCT, Diabetes Control and Complications Trial; IFCC, International Federation of Clinical Chemistry;
IQR, interquartile range.
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The validation was carried out using the three parameter model (baseline retinopathy, duration of diabetes
and HbA1c), and the proportions progressing to STDR by quintiles of risk within each programme were
estimated and are shown in Figure 10. Descriptions of the clinical information and rates of progression to
STDR within each risk quintile by programme are shown in Table 19.
The proportion of patients in these three programmes who developed STDR or had no STDR on the date
of censoring is shown in Figure 11 by quintile of risk. The component levels of STDR are shown. This
demonstrates that the severity of STDR is associated with risk estimation, as was seen in the
Gloucestershire validation data set (see Figure 4 and Table 11).
Model fit has been assessed using ROC curves and is shown in Figure 12.
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FIGURE 10 Validation in three English programmes. (a) Programme A; (b) programme B; and (c) programme C.
Patients grouped into quintiles of risk within each programme (i.e. Group 1 contains those whose risk score is
0–20th centile, Group 2 is 21–40th centile, Group 3 is 41–60th centile, Group 4 is 61–80th centile, Group 5 is
81–100th centile).
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TABLE 19 Validation results
Programme A: n= 17,634 B: n= 1223 C: n= 1083
AUC at 3 years (95% CI) 0.782 (0.762 to 0.803) 0.836 (0.78 to 0.884) 0.815 (0.714 to 0.897)
PYs 42,535 5046 4242
Number of cases of STDR 845 94 81
Overall event rate 20/1000 PYs 19/1000 PYs 19/1000 PYs
Proportion with DR in 0/1/2 eyes (%)
DR quintile 1 100/0/0 100/0/0 100/0/0
DR quintile 2 100/0/0 100/0/0 100/0/0
DR quintile 3 99.8/0.2/0 99.2/0.8/0 100/0/0
DR quintile 4 79.9/20.1/0 66.9/33.1/0 64.5/35.5/0
DR quintile 5 26.5/28.8/44.7 25/33.6/41.4 15.3/29.6/55.1
HbA1c (mmol/mol), median (IQR)
HbA1c quintile 1 45 (42–48) 42 (39–44.5) 43 (41–46)
HbA1c quintile 2 52 (49–54) 50 (46–52) 51 (47.5–53)
HbA1c quintile 3 58 (54–63) 57 (52–61) 58.5 (54–63)
HbA1c quintile 4 67 (56–76) 66 (50–77) 65 (51–79)
HbA1c quintile 5 67 (56–89) 67.5 (55–92) 65 (53–83)
Duration of diabetes (years), median (IQR)
Duration quintile 1 1.5 (0.35–3.34) 1.7 (0.9–3.3) 0.9 (0.3–2.1)
Duration quintile 2 3.8 (1.4–6.4) 2.7 (1.2–4.8) 2.2 (0.7–4.2)
Duration quintile 3 6.4 (3.4–9.2) 4.8 (1.9–7.2) 4.1 (1.1–6.9)
Duration quintile 4 6.8 (2.7–11.0) 4.3 (1.4–7.9) 4.8 (1.0–7.7)
Duration quintile 5 9.8 (5.1–15.8) 7.2 (2.0–12.8) 8.2 (1.5–14.7)
Event rate (per 1000 PYs)
Event rate quintile 1 3 1 2
Event rate quintile 2 4 9 0
Event rate quintile 3 7 6 7
Event rate quintile 4 12 24 15
Event rate quintile 5 74 55 79
PY, person-year.
AUC values were calculated at 3 years using bootstrapping of 1000 samples each.
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FIGURE 11 Severity of DR at event or censoring. (a) Programme A; (b) programme B; and (c) programme C.
DOI: 10.3310/hta19740 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 74
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Scanlon et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
35
Validation of model by ethnic group
The participants in programme A are 98% Caucasian, and so this programme cannot be used to examine
the effect of ethnicity.
Programme B had too few people with clinical information from primary care in the data set to fit
the model with one SE and clinical information and so it was only possible to validate the model that uses
two SEs to stratify patients by baseline risk. The risk estimator from this model was applied and ethnic
group categories fitted in a Cox proportional hazards model. Results are shown in Figure 13 and Table 20.
Overall, the HR is over 50% higher for those of African or Caribbean ethnicity and 24% higher for those
of other white ethnicity; in this category, many patients are Brazilian and Portuguese but the coding does
not enable this to be broken down further.
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FIGURE 12 ROC for model with clinical information and one SE. (a) Programme A; (b) programme B; and
(c) programme C.
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FIGURE 13 Validation in programme B using the risk stratification based on two SEs. Progression to STDR.
(a) All risk groups; (b) high risk; (c) intermediate risk; and (d) low risk.
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The ethnicity coding in programme C is unreliable. The data for those with three SEs, with the first two
episodes showing no referable retinopathy, are shown in Table 21. Over half the people in the cohort
(54.8%) have no ethnic group recorded. There are 1257 people coded as African, yet the 2009 Office for
National Statistics population estimates have 3100 people of African ethnicity in the whole area, and the
African and Caribbean populations are about the same size. It appears that this coding may well be
erroneous. Certainly, this level of uncertainty means that further analysis would be unreliable.
TABLE 20 Results of fitting risk models to programme B
Ethnic group n
Sex (male/
female), %
Type of
diabetes
(type 1/type
2/other), %
Duration of
diabetes at second
screening (years),
median (IQR)
Age at diagnosis
of diabetes (years),
median (IQR)
Hazard ratio
(95% CI)
adjusted for
risk category
African 3305 50.4/49.6 3.2/96.2/0.6 3 (1–6) 47 (40–55) 1.55
(1.33 to 1.80)
Caribbean 3993 41.8/58.1 2.6/97.1/0.3 4 (1–9) 57 (47–66) 1.58
(1.38 to 1.81)
Other white 1728 54.1/45.9 9.4/90.1/0.5 4 (1–9) 55 (44–64) 1.24
(1.03 to 1.48)
White British 9478 54.8/45.2 9.6/90.1/0.3 4 (1–8) 57 (46–66) 1.0
IQR, interquartile range.
TABLE 21 Ethnicity coding in programme C
Ethnic group Code n Proportion (%)
Null Null 5198 30.3
Not stated Z 4195 24.5
White British A 3596 21.0
Any other S 2220 12.9
African N 1257 7.3
Other white C 236 1.4
Pakistani J 163 1.0
Caribbean M 82 0.5
Indian H 81 0.5
White Irish B 79 0.5
Any other Asian L 14 0.1
Any other black P 12 0.1
Mixed race white: African-Caribbean D 8 0.05
Bangladeshi K 8 0.05
Any other mixed race G 4 0.02
Mixed race white: African E 1 0.01
Chinese R 1 0.01
Total 17,155
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Conclusion
We have used data from three large, heterogeneous DESPs in England to validate the clinical model
developed in Phase 1 (see Chapter 5).
l Within each of these three English screening programmes, the risk model discriminates well between
those at very low risk and those at very high risk of progression to STDR.
l The model would be suitable for development of personalised screening intervals.
l Further validation in other data sets with robust ethnicity information would be useful.
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Chapter 7 Phase 3: monitoring interval approach
Rationale
The reasons for the current annual monitoring interval are unclear and may be more historical than
evidence-based. In recent years, a statistical methodology has been developed for studying the
time intervals in monitoring and screening programmes and their consequences for patients and service
providers. In this project we extended that methodology to DR screening to confirm (or otherwise)
the appropriateness of annual screening as the default for retinal photography.
Data set
We used the same longitudinal data on digital photographs and risk factor data as the risk-factor approach
of Chapter 5.
Overview of method
We used a statistical method that has been used extensively to model the course of chronic diseases,
including DR,63 and to evaluate screening programmes.64 This project advances on the risk-factor approach
of Chapter 5 (Phase 1) by allowing classification error in retinopathy grades by using a hidden (unobserved)
Markov model to estimate simultaneously the progression of disease and the potential for screening to
misclassify the true state of DR. The factors contributing to the risk score of Phase 1 were included as
explanatory variables.
Retinal screening gives a composite categorical measure (retinopathy grade and presence or absence of
maculopathy). We converted this into seven states or levels relating to the early stages of DR and degrees
of sight-threatening or referable disease. We applied the modelling methods to the GDESP data to
obtain estimates of disease progression and the probability of misclassification. We calibrated the rates of
FP and FN tests to estimates reported in the literature.
We estimated rates of true- and false-positive and -negative tests under the following scenarios:
l annual testing (base case)
l at other fixed intervals including 6-monthly, and every 2, 3 and 5 years.
The impact of varying levels of non-attendance was considered based on estimated attendance rates from
our data and, in sensitivity analyses, from the literature. Simulations were cross-checked against other
calculation methods, and further checked against the observed data to verify the internal validity of
the model.
Expected outcome
An evidence-base for the existing annual monitoring interval or a recommended alternative to annual
monitoring as the default.
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Introduction
Diabetic retinopathy and maculopathy are complications of diabetes that can lead to vision loss. Regular
screening using fundus photography is recommended for all people with diabetes with referral to specialist
care for optimal treatment. Recommendations for the frequency of screening for eye disease and
subsequent monitoring for further progression in clinical guidelines are inconsistent. NICE recommends65
annual screening, whereas the American Diabetes Association recommend66 annual screening initially but
suggest that less frequent examinations (2–3 years) may be considered following one or two normal eye
examinations. The SIGN guidelines21 suggest annual screening in general but every 2 years for people with
no evidence of retinopathy. Australian guidelines67 for the management of diabetes suggest 2-yearly
screening in people with no retinopathy, but annual screening for higher-risk groups and more frequent
monitoring after retinopathy has been detected. Canadian guidelines68 differentiate between diabetes type
and suggest annual screening for people with type 1 diabetes and 1–2-yearly screening for those with
type 2 diabetes. The IDF guidelines69 recommend 1–2-yearly intervals for those with no disease, yearly
intervals for those with minimal unchanged retinopathy and 3–6-monthly intervals if there is worsening
since the last examination.
Given that screening using digital photography is imperfect and subject to various sources of variation, there is
potential for people to be over-referred to specialist ophthalmology services in the absence of sight-threatening
disease, or under-referred, when screening fails to detect referable level disease. In addition, imperfect methods
can give the impression of change over time (progression or deterioration) when, in fact, the condition is stable.
The consequences of such errors are numerous and wide ranging. When people are over-referred to specialist
eye clinics, health-care resources (time and money) are wasted that could be better used to treat people with
consequential disease, and the extra appointments are inconvenient for patients and may cause unnecessary
anxiety. Under-referrals may mean a window of opportunity is missed for optimal interventions and could result
in a poorer prognosis. Finally, misclassification can lead to more frequent and unnecessary monitoring which
subsequently increases the risk of over-referral or, conversely, less frequent monitoring and unnecessary delays
in detection of true change.
The aim of this study was to use routinely collected screening data to model the natural history of DR and
maculopathy and the rates of correct and incorrect assignments using a statistical model. These estimates
of disease progression and rates of over- and under-referral can be used to compare different screening
intervals in cost-effectiveness models (Chapter 8).
Methods
The criteria for screening and grading of digital photographs are as follows. At each screening assessment,
visual acuity was assessed using logarithm of the minimum angle of resolution (logMAR) charts and two
colour digital retinal photographs of two standard 45-degree fields (macula and disc centred) per eye after
dilatation of the pupils. Photographs are then graded by trained assessors in a central location for the
presence of maculopathy or DR and the severity of DR. The English screening programme grades retina
images39 as R0 if there is no detectable DR and as M0 if there is no evidence of maculopathy. Images are
graded R1 if there is at least one microaneurysm and/or retinal haemorrhage. R2 (pre-proliferative) identifies
the presence of multiple haemorrhages and/or definite intraretinal microvascular abnormality (IRMA) and/or
venous beading and/or reduplication. R3 level (PDR) indicates the presence of neovascularisation. M1
(maculopathy) identifies the presence of two-dimensional photographic markers of diabetic maculopathy,
specifically an exudate within 1-disc diameter of the centre of the fovea, a group of exudates within the
macula, or any microaneurysm or haemorrhage within 1-disc diameter of the centre of the fovea, but only if
associated with a best visual acuity of worse than 0.3 logMAR (equivalent to Snellen 6/12).39
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For statistical analysis, we amalgamated retinopathy and maculopathy grades for both eyes into a
univariate outcome with seven levels: (1) no DR in both eyes (R0M0 R0M0); (2) background in one eye, no
detectable DR in the other eye (R1M0 R0M0); (3) background retinopathy in both eyes (R1M0 R1M0);
(4) pre-proliferative DR or PDR in one eye, no detectable DR or background in the other (R2+M0 R0/1M0);
(5) pre-proliferative DR or PDR in both eyes (R2+M0 R2+M0); (6) maculopathy in one eye and any DR
(M0 M1); and (7) maculopathy in both eyes and any DR (M1 M1).
Model structure
We treat the seven levels of retinopathy and maculopathy described above as states in a Markov model.
We used a continuous-time hidden Markov model to estimate simultaneously the transition rates
(intensities) between states and the probabilities of misclassification. Markov models have been used
extensively to model disease progression and to evaluate screening strategies. A hidden Markov model
accounts for the fact that the true disease state is not always reflected by the test. In this context, the true
disease state could be thought of as the potential grade determined by seven field stereo-photography or
similar gold-standard tests for DR corresponding to each screening grade.
Model structure and assumptions were informed by what was known about DR, the evaluation needs and
discussions with clinical experts, health economists, statisticians and epidemiologists involved in this project.
This consisted of an iterative process as the conceptual framework was revisited following the analysis of data
and the health economics evaluation. The following modelling assumptions about disease progression are
required: (1) as there is good evidence to suggest that background retinopathy can develop and subsequently
disappear,70 movement back and forth was permitted between the states corresponding to no detectable
retinopathy and background retinopathy (levels 1, 2 and 3); (2) once disease has progressed to at least
pre-proliferative retinopathy (level 4 upwards), remission to level 3 or below is assumed to be impossible;
(3) we assumed that eyes cannot develop pre-proliferative retinopathy without first developing background
retinopathy; hence, there is no direct link from state 1 to pre-proliferative retinopathy or proliferative
retinopathy states (4 and 5); (5) for model parsimony, and because advanced retinopathy or maculopathy
leads to treatment, we do not consider progressions from either level 5 (pre-proliferative or proliferative
retinopathy in both eyes) or state 7 (maculopathy in both eyes). Figure 14 is a graphical representation of the
model for underlying disease progression.
State 1
No DR
(R0M0 R0M0) 
State 2
Background
in one eye
(R1M0 R0M0) 
State 3
Background
in both eyes
(R1M0 R1M0)
State 4
Pre-proliferative
or proliferative
in worst eye
(R2/3M0 R0/1/M0)
State 5
Pre-proliferative
or proliferative
in both eyes
(R2/3M0 R2/3M0)
State 6
Maculopathy
in one eye
(R1/2/3M1
R1/R2/R3M0)
State 7
Maculopathy
in both eyes
(R1/2/3M1
R1/2/3M1)
FIGURE 14 Graphical representation of the model for progression of diabetic eye disease. Arrows from one state to
another represent instantaneous transitions to be estimated. Absence of arrows indicates that instantaneous
progression is not possible.
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We did not impose modelling assumptions on the probabilities that any given state is misclassified, during
retinopathy grading, as another. The model therefore estimates a 7 × 7 matrix of instantaneous transition
probabilities with forced 0 entries representing the modelling assumptions listed above, and an
unrestricted 7 × 7 matrix representing misclassification probabilities.
The model was fitted using the msm function71 in R version 3.0.1 (The R Foundation for Statistical
Computing, Vienna, Austria).72 The final model was derived by adding potentially explanatory variables
separately and then together in turn in order to find the model with the lowest deviance (–2 log
likelihood). The final model adjusted for duration of diabetes at the first SE, baseline HbA1c and serum
cholesterol level. We explored adjusting the model for type of diabetes, but the low number of people
with type 1 (≈900) in the screening cohort made the model too unstable. In the case of blood pressure,
age and sex, these did not significantly improve the fit of the model and so were not included in the
final model.
Estimated over- and under-referrals attributable to screening
We used the model to calculate the FP and FN rates for referable disease, defined as pre-proliferative or
proliferative retinopathy or any maculopathy, at a screening visit. In a post-hoc secondary analysis, we also
summarised these rates under varying assumptions about case mix to enable comparison with previously
published studies.
We then considered the FP and FN rates over time in screening programmes with 6 months, 1 year,
3 years or 5 years between screening visits. Using the fitted intensity and error matrices, we calculated
the expected number of people with referable eye disease, the number of over- and under-referrals and the
ratio of false to true referrals at follow-up visit, stratified by observed state at baseline visit. Results are
presented for two cohorts, one with risk factor levels (duration of diabetes, HbA1c, cholesterol) comparable
to the Gloucester cohort, and a ‘high-risk’ cohort group with a longer (10 years) duration of diabetes,
poorly controlled glycaemia (baseline HbA1c of 65mmol/mol) and elevated cholesterol (6 mg/l). Results are
presented in terms of screening 10,000 people to aid interpretation.
Results
From a total of 14,810 people, 68,992 examinations results were extracted from the screening service
database. The modelling data set consisted of 65,839 grades from 14,187 people. Observations were
excluded if retinopathy or maculopathy grade were missing from either eye or were obviously duplicate
entries, and people were excluded if they only had one useable observation or did not have baseline
HbA1c, serum cholesterol or duration of diabetes recorded. The median number of examinations was
5 [interquartile range (IQR) 3–6] and the median interval between examinations was 1.04 (IQR 0.99–1.17)
years. Characteristics of the cohort at baseline are given in Table 22.
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Table 23 shows the raw unadjusted counts of transitions across all individuals in the cohort. These
represent the number of times one grade has been followed by another. Row percentages are also given
and can be interpreted as empirical probabilities of observing changes in consecutive examinations.
The estimated transition intensity matrix is shown in Table 24.
The matrix of estimated error probabilities is given in Table 25. Here, off-diagonal elements represent
probabilities of grading errors, and diagonal elements probabilities of correct grading.
The duration of diabetes and baseline HbA1c and serum cholesterol were independent predictors of true
progression of DR. To ensure model convergence, covariates effects were standardised and constrained to
be equal for each of the 11 forward transition intensities and all three backward transition intensities.
Table 26 shows the proportional HRs on forward and backward transition intensities for the three covariates.
TABLE 22 Baseline characteristics of the modelling cohort
Characteristic Level n= 14,187
Retinopathy levels, n (%) No detectable DR in either eye 8571 (60.4)
Background DR in one eye 2666 (18.8)
Background DR in both eyes 1835 (12.9)
STDR in one eye and no maculopathy 161 (1.1)
STDR in both eyes and no maculopathy 132 (0.9)
Maculopathy in one eye 563 (4.0)
Maculopathy in both eyes 259 (1.8)
Sex, n (%) Male 8061 (56.8)
Female 6126 (43.2)
Age (years), median (IQR) 64 (56–72)
HbA1c (mmol/mol), median (IQR) 51.0 (43.5–61.0)
Serum cholesterol (mmol/l), median (IQR) 4.3 (3.7–5.0)
Duration of diabetes (years), median (IQR) 2.4 (0.75–7.2)
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The numbers of referrals (for maculopathy and retinopathy) and the numbers which represent true,
over- and under-referrals and the ratio of false to true referrals were calculated using the estimated intensity
and error matrices. Table 27 shows the results for people with no detectable retinopathy at baseline and
the true and false referrals when the next screen occurs 6 months, 1, 3 or 5 years later. Table 28 shows the
results for people with background retinopathy in one eye and Table 29 shows the results for people with
background retinopathy in both eyes at intervals of 3, 6 and 12 months. Tables 30–32 show equivalent
results for high-risk patients.
TABLE 26 Estimated HRs for change in (standardised) baseline variables
Covariate Transitional Estimated HR (95% CI)
HbA1c (equivalent to change in increments of 15mmol/mol) Progression 1.46 (1.41 to 1.51)
Regression 0.95 (0.86 to 1.04)
Duration of diabetes (equivalent to change in increments
of 7.8 years)
Progression 1.21 (1.16 to 1.25)
Regression 0.21 (0.16 to 0.27)
Total cholesterol (equivalent to change in 1.1mmol/l) Progression 1.0 (0.97 to 1.1)
Regression 1.1 (1.04 to 1.2)
All forward transitions and backward transitions are constrained to have the same hazard for each of the covariates.
TABLE 27 Number of people referred by screening after baseline grade of ‘no detectable retinopathy’ and
low-risk CRF
Baseline
screening
result
Number with
true referable
disease
Referrals from
screening that
are correct
Referrals from
screening which
are false
Not referred by
screening when
referable disease
is present
Ratio of
over-referrals/true
referrals
No detectable retinopathy, n per 10,000 screened
Baseline 2 – – 2
6 months 5 4 54 1 12.1
1 year 10 8 66 2 7.8
3 years 50 41 111 9 2.7
5 years 125 103 149 22 1.4
Standardised to: duration of diabetes (6 years), HbA1c (55mmol/mol) and total cholesterol (4.4mmol/l).
TABLE 28 Number of people referred by screening after baseline grade of ‘background retinopathy in one eye’
and low-risk CRF
Baseline
screening
result
Number with
true referable
disease
Referrals from
screening that
are correct
Referrals from
screening which
are false
Not referred by
screening when
referable disease
is present
Ratio of
over-referrals/true
referrals
Background retinopathy in one eye, n per 10,000 screened
Baseline 31 – – 31
6 months 51 41 179 9 4.3
1 year 75 61 193 14 3.1
3 years 208 171 230 37 1.3
5 years 373 309 247 64 0.8
Standardised to: duration of diabetes (6 years), HbA1c (55mmol/mol) and total cholesterol (4.4mmol/l).
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Higher-risk patients
TABLE 29 Number of people referred by screening after baseline grade of ‘background retinopathy in both eyes’
and low-risk CRF
Baseline
screening
result
Number with
true referable
disease
Referrals from
screening that
are correct
Referrals from
screening which
are false
Not referred by
screening when
referable disease
is present
Ratio of
over-referrals/true
referrals
Background retinopathy in both eyes, n per 10,000 screened
Baseline 588 – – 588
6 months 709 579 551 131 1.0
1 year 825 675 526 150 0.8
3 years 1234 1021 444 213 0.4
5 years 1577 1319 383 258 0.3
Standardised to: duration of diabetes (6 years), HbA1c (55mmol/mol) and total cholesterol (4.4mmol/l).
TABLE 30 Number of people referred by screening after baseline grade of ‘no detectable retinopathy’ and
high-risk CRF
Baseline
screening
result
Number with
true referable
disease
Referrals from
screening that
are correct
Referrals from
screening which
are false
Not referred by
screening when
referable disease
is present
Ratio of
over-referrals/true
referrals
No detectable retinopathy, n per 10,000 screened
Baseline 2 – – 2
6 months 7 6 61 1 9.9
1 year 17 14 80 3 5.7
3 years 111 91 159 20 1.7
5 years 300 248 228 52 0.9
Standardised to: duration of diabetes (10 years), HbA1c (65mmol/mol) and total cholesterol (6mmol/l).
TABLE 31 Number of people referred by screening after baseline grade of ‘background retinopathy in one eye’
and high-risk CRF
Baseline
screening
result
Number with
true referable
disease
Referrals from
screening that
are correct
Referrals from
screening which
are false
Not referred by
screening when
referable disease
is present
Ratio of
over-referrals/true
referrals
Background retinopathy in one eye, n per 10,000 screened
Baseline 31 – – 31
6 months 62 51 194 11 3.8
1 year 105 86 222 19 2.6
3 years 368 304 303 65 1.0
5 years 730 607 347 123 0.6
Standardised to: duration of diabetes (10 years), HbA1c (65mmol/mol) and total cholesterol (6mmol/l).
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Conclusion
Our results show that annual screening for DR is associated with a disproportionate number of FPs or
over-referrals, and extending the interval of screening reduces the occurrence of over-referrals. The number
of FPs far outweighs the number of FNs even though the specificity (1 – FP rate) of the screening test is
high. This occurs because the population being screened consists largely of people with no detectable DR
or background DR and, hence, FP error rates are ‘amplified’ by screening.73 Waiting longer to rescreen
reduces the number of errors as the balance of non-referable disease to referable-level disease starts to tilt
towards the latter rather than the former. Screening less frequently is likely to reduce significantly the cost
of screening and reduce the number of unnecessary referrals to specialist eye services. However, longer
intervals of screening will mean inevitable delays in referring a small number of people with true STDR for
either closer monitoring or therapy. Our modelling suggests that these FNs will mostly comprise people
with pre-proliferative DR or maculopathy, and, although this requires referral to ophthalmology, it is not
considered as urgent as PDR. The implications for such delays in people with pre-proliferative disease or
maculopathy are not fully understood but could be detrimental.
Estimation of the rate of progression
Our approach to modelling the progression of DR takes into account misclassification (over- and
under-referral) and hence is less susceptible to the bias associated with standard methods to calculate
incidence in the presence of an imperfect test.74 However, owing to the relatively low estimated error
rates, our model produces similar estimates of the rates of progression of DR as reported elsewhere.
For example, Liu et al.75 used a multistate Markov model (not accounting for error in the test) to model
the average sojourn time in states of DR using repeated examinations using fundus examination.
They reported average dwelling time with no DR as 10.86 years and background DR as 8.33 years.75
Estimated average sojourn time from our hidden Markov model in the no DR, background DR in one
eye and background DR in both eyes states are 9.3 years (95% CI 8.5 years to 10.3 years), 4.3 years
(95% CI 3.7 years to 4.9 years) and 5.6 years (95% CI 4.8 years to 6.6 years).
The risk of developing STDR as predicted by the model is also comparable to those risks reported in the
UKPDS.70 Our model suggests that the true incidence of any retinopathy after 6 years is 39% and 1.7%
for STDR. In the UKPDS, the observed incidence of any retinopathy was 40.6% and 2.7% for STDR.
TABLE 32 Number of people referred by screening after baseline grade of ‘background retinopathy in both eyes’
and high-risk CRF
Baseline
screening
result
Number with
true referable
disease
Referrals from
screening that
are correct
Referrals from
screening which
are false
Not referred by
screening when
referable disease
is present
Ratio of
over-referrals/true
referrals
Background retinopathy in both eyes, n per 10,000 screened
Baseline 588 – – 588
6 months 767 627 566 140 0.9
1 year 942 773 553 170 0.7
3 years 1606 1336 504 270 0.4
5 years 2210 1863 460 347 0.2
Standardised to: duration of diabetes (10 years), HbA1c (65mmol/mol) and total cholesterol (6mmol/l) as per the average
seen in the Gloucester cohort.
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Estimation of misclassification rates
Our modelling results give valuable insights into the chance of correct or incorrect assignments
(misclassifications) attributable to screening. As might be expected, it is common for screening to find
background retinopathy in one eye when there is none (11 in 100), and for screening to miss background
DR when it is present (21 in 100). At present, these errors will have little or no bearing on the management
of such patients, as current recommendations for screening do not differ for those with no detectable DR
or background DR.
False positives (over-referrals) are more likely when there is true background DR present in one or both
eyes. We estimate that if 100 people with background DR in one eye undergo screening, two will be
referred with suspected STDR (either M1, R2 or R3). When background DR affects both eyes, we expect
nine in 100 to be referred in error.
Our modelling also suggests that a number of referrals are missed by screening. For 100 people with true
STDR (but no maculopathy) in one eye, 25 will be undergraded and not referred; for 100 people with
true STDR (no maculopathy) in both eyes, four are likely to be undergraded and not referred. For
100 people with true referable STDR and maculopathy present in one eye, we estimate that 16 will not be
referred, and this drops to two in 100 when there is true STDR in both eyes (with maculopathy).
Comparison with external estimates
Direct comparison of our estimated misclassification rates with external and independent estimates is
compromised by a lack of uniformity of grading systems, differences in screening methods and the varying
case-mixes of people included in such studies. We found five diagnostic accuracy studies76–80 in which digital
photography was compared with a reference test of either slit-lamp biomicroscopy or seven field stereo
photography and used similar criteria to the DESP to define STDR. Four of these studies reported specificity
from which we could calculate the false-positive rates (FPR). From the paper by Stellingwerf et al.80 we
derived an estimated FPR of 0.9%, from Scanlon et al.,78 a FPR of 3.8%, from Scanlon et al.,79 a FPR of
13.9%, and from Olson et al.,77 a FPR of 12.7%. A direct comparison of these estimates of the FPR with our
misclassification rates can only be made if the proportions of people with no DR or background DR in one
or both eyes is known (case mix), so that we can derive an appropriate weighted estimate. However, we
know that our model estimated FPR would be < 1% if all participants had no DR and would reach an upper
bound of 9% if participants had background DR in both eyes. These estimates are within the FPRs reported
by Stellingwerf et al.80 and Scanlon et al.78 but lower than those of Olson et al.77 and Scanlon et al.79
All five studies reported sensitivities from which we could derive the false-negative rate (FNR). The FNRs
reported in the four studies using slit-lamp biomicroscopy as the reference test (4.8% in Stellingwerf
et al.,80 3.8% in Olson et al.,77 8% in Kalm et al.76 and 12.2% in Scanlon et al.79) were considerably lower
than the estimate of 19.7% in Scanlon et al.,78 which used seven field stereo photography as a reference
test. As with the FPR, we can only compare lower and upper bound estimates of the FNR. The FNR
predicted by our model ranges from 2% to 25% depending on the relative mix of referable DR being
studied. These estimates are comparable to the FNRs reported in the literature.
Empirical evidence for the probability of overgrading DR and diabetic maculopathy is rare. In the largest
study we found, Healy et al.56 regraded images from 1501 patients referred for STDR between 2008 and
2011. They reported that the most common source of error from the screening service was grading R1 as
R2 (in 16% of all discrepant images) or grading R2 as R3 in the absence of new vessels (4%). After
reviewing images that were referred for diabetic maculopathy, they found that the screening service
misclassified 13% eyes as maculopathy in the absence of characteristics that warrant referral.
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Evaluating different intervals of screening
Using our model we estimate that annual screening in people with no detectable retinopathy in either eye
at baseline would lead to nearly eight times as many false referrals than true referrals. If the interval
of screening were to be extended to 3 years then the ratio of false to true referrals is reduced to 2.7 and
1.44 after 5 years. When a previous screen has found background retinopathy in one eye then annual
screening leads to 3.1 unnecessary referrals for every correct referral and this reduces to 1.3 referrals after
3 years and 0.8 referrals after 5 years. When background retinopathy has been detected in both eyes at
baseline, screening at 6 months produces equal numbers of correct and unnecessary referrals (ratio= 1.0)
and screening 1 year later yields more true than false referrals.
For people with elevated systemic risk factors, the ratio of false to true referrals is reduced for each initial
grade of DR and as the interval of screening increases, but not to the extent that baseline DR status does.
Therefore, higher levels of systemic risk factors in conjunction with evidence of background DR may
warrant more frequent screening, leading to individualised screening intervals, a concept which has already
been trialled in the Netherlands.81
Discussion
Retinopathy screening is widely recommended, but guidelines for the frequency of screening are
inconsistent. Evidence for these recommendations are largely based on consensus opinion and convenient
timeframes rather than solid evidence. We have presented a model-based approach to evaluating screening
programmes that can be used to construct evidence-based guidelines for the intervals of screening based
upon the current screening grade and CRFs.
The significant advantage to a modelling approach is that it enables the comparison of a wide range of
different screening strategies over long periods of time, which is infeasible in a controlled trial setting.
Because all models make a number of assumptions, there are a number of inevitable limitations to such
analyses. We could not adjust progression rates for type of diabetes (type 1 vs. type 2) and, hence, we
were unable to evaluate screening strategies for this subgroup. However, diabetes type does not seem
independently to affect the risk of progression over and above diabetes duration, HbA1c and status of DR
(see Chapter 5). Another potential criticism of our evaluation of screening is that we have assumed that
compliance to the screening programme is 100% and we have not attempted to adjust for varying
take-up rates and sporadic attendance. This is likely to reduce the effectiveness of screening further,
especially if attendance is associated with patients’ poorer control of their diabetes and subsequent
greater risk of developing STDR.82 However, the effect of non-attendance on screening effectiveness is
addressed in the health economic analysis in Chapter 8.
We have shown that with a model-based approach it is possible to describe both the underlying
progression of DR and the rates of misclassification attributable to screening using routinely collected
screening data. Estimates from these models can be directly incorporated into cost-effectiveness models of
different screening strategies and guide future recommendations for screening.
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Chapter 8 Phase 4: cost-effectiveness of differing
screening intervals in diabetic retinopathy screening
Introduction
No firm evidence or evidence-based consensus exists as to the optimal frequency of testing for DR.
Although previous studies have assessed the cost-effectiveness of differing intervals for DR screening, the
evidence is mixed. The aim of this work was to determine if assigning diabetic patients to differing DR
screening intervals using a risk estimation model is cost-effective compared with the current English
national screening programme (i.e. annual screening for all eligible people with diabetes aged 12 years
and over).
Objective
Diabetes is one of the most common chronic diseases, placing a great economic burden on society owing
to its increased health-care expenditures and lost productivity. Although the treatment of diabetes on
its own is costly, its complications are the major contributors to health-care costs. Among the main
diabetes-related complications is DR, which has been shown to be, until recently, the leading cause of
blindness in the working age population10 in the UK. DR is treated effectively with laser photocoagulation,
although this has been found to be cost-effective only if retinopathy is detected before irreversible damages
take place.13,15,16 Therefore, in order for DR treatment to be cost-effective, diagnosis has to be timely, with
published evidence showing that screening for STDR is highly cost-effective.17–20,83 In the UK, results from
published studies also highlight the cost-effectiveness of screening for DR,84 with James et al.85 showing that
a screening programme using retinal photography was cost-effective compared with opportunistic screening.
In 2003, a national screening programme was introduced in England, recommending digital imaging as
the preferred method of retinal photography for screening and mandating that local programmes respond
to local needs with different models of care,86 with eye screening to be performed at time of diabetes
diagnosis and repeated annually thereafter. Annual DR screening was also recommended in
NICE guidelines.65,87
However, despite these recommendations, no firm evidence or evidence-based consensus exists as to the
optimal frequency of testing for DR. SIGN reported that patients with diabetes with no detected retinopathy
could be screened every 2 years, with all other patients being screened at least annually.21 Given the rising
numbers of people identified by primary care practices as having diabetes, a rise of over 100,000 people
annually,5 and lower rates of progression to PDR and severe visual loss,11,12 reflecting in part improvements
in general diabetes care, there is an argument for modifying DR screening recommendations. Therefore, the
aim of this work is to determine whether assigning diabetic patients to differing DR screening intervals
using a risk estimation model is cost-effective compared with the current English national screening
programme (i.e. annual screening for all people with diabetes).
Existing research
A published systematic review assessing economic evidence surrounding differing DR screening frequencies
showed that the evidence on cost-effectiveness was mixed.46 The review only identified three studies, one
performed in the USA and two in the UK.
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The UK study by Brailsford et al.88 found similar results to the US study. The study, which also used a
decision analytic model to assess the cost-effectiveness of DR screening in both type 1 and type 2 diabetes
patients, found that a 30-month screening interval was the most cost-effective option. However, in
contrast to these two studies, Davies et al.48 found that screening diabetic patients less than once a year
would not be any more cost-effective than screening them every year. The study also based its work on a
decision analytic model populated using results obtained from the published literature. A finding common
in both UK studies was that screening type 1 diabetes patients was more cost-effective than screening
type 2 diabetes patients.
There were, however, important limitations to both of the UK studies. Both studies used sight years saved
as their main outcome measure, rather than a more generalisable health outcome, such as QALYs, that
can be readily compared across intervention and disease areas, and for which willingness-to-pay thresholds
exist to determine cost-effectiveness. The two studies also failed to include in their models the additional
costs to the health-care service of patients losing sight or going blind, which have recently been shown to
be considerable and non-negligible.89 Finally, data in the two UK studies were derived from a wide range
of sources and diabetic populations. As a result, both studies had to undertake numerous assumptions as
to how best to synthesise the available data.
The US study examined the cost-effectiveness of differing DR screening intervals for type 2 diabetes
patients in the USA.27 The authors employed a Markov model using QALYs as the main outcome measure,
with costs being assessed from a third-party payer perspective. Using a threshold of US$50,000 per QALY
gained, or less, as an indication of a cost-effective intervention, the authors reported that annual screening
for all type 2 diabetes patients was not warranted on the basis of cost-effectiveness.
An additional US study, published after the review by Jones and Edwards,46 found that annual screening
was costly and added little benefit compared with biennial eye evaluation.90 In addition, the authors found
that the cost-effectiveness of biennial screening depended on the ability of the screening programme to
detect other eye conditions. If a screening programme was unable to detect such conditions, then a
simple telemedicine programme using acuity eye charts or screening questions became the most
cost-effective alternative.
Methods
Interventions under study
For all the screening strategies under study, DR screening consisted of two digital photographs on two
fields, with mydriasis (i.e. eye dilatation) to maximise image quality. We therefore modelled the
cost-effectiveness of the following screening intervals for all patients with diabetes, including current
practice in the English national screening programme, in which all patients with diabetes are
screened annually:
1. DR screening every 6 months
2. DR screening every year (current practice)
3. DR screening every 2 years
4. DR screening every 3 years
5. DR screening every 5 years.
In addition, the cost-effectiveness of these screening intervals was assessed in patient subgroups at
different risks of developing STDR or maculopathy. We used two different risk stratification models
(see Chapter 5), one based on the results of two consecutive initial SEs and another based on the results of
one SE in conjunction with CRF data (Table 33).
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Common to all screening strategies, a diabetic patient was offered diabetic screening at the specified time
intervals which could result in receiving screening or not, conditional on the screening uptake (Figure 15).
Patients who were identified at screening to have pre-proliferative retinopathy (i.e. R2), PDR (i.e. R3) or
diabetic maculopathy (M1) were referred to Hospital Eye Services (HES) for further tests and/or assessment
by an ophthalmologist. Not all referred patients chose to attend their clinical appointment.
If diagnosis of DR (R2 or R3) or diabetic maculopathy (M1) was confirmed in at least one eye in the HES,
then, depending on clinical need, patients would either be monitored by HES every 6 months, treated
with either laser photocoagulation or antiangiogenic therapy, or referred back to the annual screening
programme (Figure 16). Once treatment occurred the patient was referred back to the screening
programme. Furthermore, patients who did not receive screening, patients who received screening but
were not referred to the HES, and patients who were referred but did not attend their appointment were
offered screening in the next time interval.
TABLE 33 Demographic characteristics of patient subgroups at differing risks of developing STDR based on the
results of two consecutive SEs or one SE in conjunction with CRF data
Risk group Initial screening results
Mean HbA1c
(mmol/mol)
Mean
cholesterol
(mg/l)
Mean age
(years)
Mean duration
of diabetes
(years)
Two SEs
Low No DR in both eyes in two
consecutive episodes (R0M0 R0M0)
51.1 4.25 66.8 5.9
Medium Background in one eye, no
detectable DR in the other eye
(R1M0 R0M0) in two consecutive
episodes
53.8 4.17 66.77 7.3
High Background retinopathy in both
eyes (R1M0 R1M0) in two
consecutive episodes
57.9 4.11 63.96 13.0
One SE and CRF data
Low No DR in both eyes (R0M0 R0M0)
or background in one eye, no
detectable DR in the other eye
(R1M0 R0M0)
48.7 4.4 64.4 2.9
Low-medium No DR in both eyes (R0M0 R0M0)
or background in one eye but no
detectable DR in the other eye
(R1M0 R0M0) or background
retinopathy in both eyes
(R1M0 R1M0)
58.9 4.6 63.9 5.0
Medium–high Same as above 58.3 4.5 63.5 5.4
High Same as above 67.9 4.5 60.4 14.8
Invited to
screen 
Non-attender
Attended screen
Negative result
Positive result:
referral to HES 
Non-attender
Attended
referral 
Screening
programme 
FIGURE 15 Screening pathway for diabetic patients offered DR screening.
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Model structure
A decision analytic model was developed to evaluate the costs, (quality-adjusted) life expectancy and
cost-effectiveness of the different DR screening strategies under evaluation. Given the natural history of DR
progression with recursive events, the most appropriate type of model was judged to be a Markov model
which was developed in Microsoft Excel (Microsoft Corporation, Redmond, WA, USA). The model was
used to simulate the natural history of the diabetic population across seven health states representing
retinopathy and maculopathy grades for both eyes (Figure 17):
1. no DR in both eyes (R0M0 R0M0)
2. background in one eye, no detectable DR in the other eye (R1M0 R0M0)
3. background retinopathy in both eyes (R1M0 R1M0)
4. pre-proliferative or proliferative retinopathy in one eye, no detectable DR or background in the other
(R2/3M0 R0/1M0)
5. pre-proliferative or proliferative retinopathy in both eyes (R2/3M0 R2/3M0)
6. diabetic maculopathy in one eye and any DR (M0 M1)
7. maculopathy in both eyes and any DR (M1 M1).
Three absorbing states were defined: maculopathy in both eyes (M1 M1); pre-proliferative or proliferative
retinopathy in both eyes (R2/3M0 R2/3M0); and death. We assumed that if patients progressed to these
three states, they would remain in that health state for the rest of their lifetime. Model structure and
assumptions were informed by what was known about DR, the evaluation needs and discussions with
clinical experts, health economists, statisticians and epidemiologists involved in this project. Hence, the
construction of the model consisted of an iterative process where the agreed conceptual framework was
revisited given new findings in the data and published literature and validity of its outputs. Such discussions
also helped to identify key uncertainties in the model structure to be explored in the sensitivity analyses.
RxM1 RxM0
R1M0 R1M0
RxM1 RxM1
D
ea
th
R0M0 R0M0  
R2/3M0 R2/3M0
R1M0 R0M0
R2/3M0 R0/1M0
D
ea
th
FIGURE 17 Model structure capturing the natural history component.
RxM1 RxM1 
R2/3M0 R0/1M0
RxM1 RxM0
R2/3M0 R2/3M0
Treatment
No treatment
Screening
programme
Monitored
every 6 months
Screening
programme
FIGURE 16 Clinical pathways of confirmed cases of STDR (R2, R3 or M1) attending referral in HES.
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The time horizon of the analysis was lifetime, and the population moved between health states according
to defined transition probabilities. The transition probabilities between the seven DR health states were
obtained from the work presented in Chapter 7. A cycle length of 6 months was considered appropriate
given the natural history of diabetic patients and the screening strategies under evaluation. Half-cycle
correction was performed and different cycle lengths were trialled (monthly, 3 months) to ascertain the
potential impact on the relative costs and effects before deciding on the 6-month cycle.
The model simulated the transition of a cohort of diabetic patients through the health states over time,
to estimate expected costs and outcomes. For example, at the start of a given cycle patients without DR in
both eyes (R0M0 R0M0) could die, develop maculopathy in one eye (M1 M0) or, alternatively, develop
background retinopathy in one eye (R1M0 R0M0). If the cycle coincided with a screening interval, the
cohort could then attend screening or not (conditional on screening uptake), be referred or not to the HES
(conditional on accuracy of the screening test), and attend or not the referral appointment (conditional on
the uptake of assessment) (Figure 15). If patients attended the HES, they could either be monitored every
6 months, treated with either laser photocoagulation or antiangiogenic therapy, or referred back to the
annual screening programme (Figure 16).
Given that slit lamp biomicroscopy is considered to be the ‘gold-standard’ for diagnosing DR, we assumed
that HES would correctly identify the true state of DR and maculopathy (i.e. 100% sensitivity and specificity).
Hence, only individuals with maculopathy (M1) or pre-proliferative/proliferative retinopathy (R2–3) were
considered for treatment or monitoring by HES. The remaining individuals were referred back to the annual
screening programme.
Patients monitored by the HES were allowed to continue progressing if they had not yet reached an absorbing
state. Once patients were treated it was assumed that they would remain in the same retinopathy and
maculopathy grades for the remainder of the simulation. This was based on evidence from clinical trials showing
that the majority of patients remaining in the same grades despite improvements in visual acuity.91 As discussed
below (see Treatment effectiveness), the benefit of treatment was captured as changes to visual acuity.
Finally, the model adopted the perspective of the UK NHS and personal social services. All costs and effects
were discounted beyond the first year of simulation using an annual discount rate of 3.5%, based on
current UK government recommendations. The price year was 2012–13 and, when necessary, costs were
inflated using the UK health sector pay and prices inflation factor.92
Model inputs
Screening uptake rate
Information on the uptake of annual subsequent DR screening was obtained from 15,877 people with
diabetes from the Gloucestershire Diabetic Eye Screening Service who attended an initial screen between
January 2005 and May 2012. Of the 108,925 possible screens that these patients could have attended,
after taking into account death and censoring (e.g. patients moving out of area), a total of 89,024
screening rounds were undertaken (82%).
To assess the characteristics independently predicting DR screening subsequent uptake rates, we performed
a logistic regression, clustered at the patient level, controlling for age, sex, subsequent screen round
attended and HbA1c and cholesterol as measured at baseline (i.e. shortly before the initial screen) (Table 34).
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Sensitivity and specificity of screening
The sensitivity and specificity of screening to detect the true states was obtained from the work presented
in Chapter 7 (see Table 25). Sensitivity and specificity of screening given true state r was defined as the
probability of being observed in state s given that the true state is r (Table 35). The error matrix presented
in Table 25 was also used to convert true states to observed states and vice versa. This was used when
data referred to observed (at screening) retinopathy grades rather than the desired true states.
Assessment at Hospital Eye Services
Using linked data from patients in the Gloucestershire Diabetic Eye Screening service referred for suspected
diagnosis of R2, R3 or M1 in any eye, and HES records, we estimated the probability of attending
a HES assessment. For this we used a random-effects logistic regression controlling for age, sex and
DR/maculopathy grade (Table 36).
TABLE 34 Predictors of uptake rates for DR screening after initial screen
Predictors Coefficient p> |z| 95% CI
Age 0.016 < 0.001 0.014 to 0.019
Sex: female 0.024 0.398 –0.032 to 0.081
Subsequent year of screening –0.135 < 0.001 –0.144 to –0.125
HbA1c –0.009 < 0.001 –0.011 to –0.007
Cholesterol –0.039 0.002 –0.064 to –0.014
Constant 1.840 < 0.001 1.619 to 2.061
Number
Number of clusters
p> χ2
82,016
13,910
< 0.001
TABLE 35 Sensitivity and specificity of screening relative to true DR and maculopathy grade
Sensitivity/specificity Mean, % 95% CI
Specificity of screening relative to true state
R0M0 R0M0 99.7 99.6 to 99.8
R1M0 R0M0 97.8 97.2 to 98.8
R1M0 R1M0 90.6 89.1 to 91.8
Sensitivity of screening relative to true state
RxM1 RxM0 82.2 77.9 to 85.5
RxM1 RxM1 98.2 94.0 to 99.0
R2–3M0 R0–1M0 75.0 71.5 to 79.5
R2–3M0 R2–3M0 96.0 93.9 to 97.4
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Treatment for diabetic retinopathy or maculopathy conditional on hospital
eye service assessment
We used data from the Gloucestershire HES to assess the probability of being treated, after each
assessment in the HES, given the true DR/maculopathy grade confirmed at the hospital (Table 37). For this
we used a random-effects logistic model.
Finally, we also used data from the Gloucestershire HES to assess which form of treatment patients
received given the true DR/maculopathy grade confirmed at the hospital. Given that we found that over
the past 5 years, the proportion of patients receiving antiangiogenic therapy has been increasing, we
limited our results to patients who had been treated from 1 January 2013 to 31 May 2014. We performed
a multinomial logit assessing the probability of the patient receiving antiangiogenic therapy or laser
photocoagulation, given the DR/maculopathy grade confirmed at the hospital and the age of the
patient (Table 38).
TABLE 36 Predictors of attendance to a HES assessment given diagnosis of STDR (R2, R3 or M1)
Predictors Coefficient p> |z| 95% CI
Age –0.012 < 0.001 –0.018 to –0.005
DR grade observed at screening
RxM1 RxM0 Reference case
RxM1 RxM1 1.222 < 0.001 1.005 to 1.440
R2–3M0 R0–1M0 0.111 0.410 –0.153 to 0.376
R2–3M0 R2–3M0 0.667 < 0.001 0.411 to 0.922
Sex: female –0.186 0.049 –0.371 to –0.001
Constant 1.232 < 0.001
Number 4164
Number of clusters 2073
p> χ2 < 0.001
TABLE 37 Predictors of treatment for STDR (R2, R3 or M1): probability of treatment
Predictors Coefficient p> |z| 95% CI
True DR grade diagnosed at HES
R2–3M0 R2–3M0 Reference case
RxM1 RxM1 2.65 < 0.001 2.22 to 3.07
R2–3M0 R0–1M0 0.025 0.870 –0.27 to 0.32
RxM1 RxM0 1.85 < 0.001 1.52 to 2.18
Constant –1.82 < 0.001 –2.10 to –1.54
Number 3926
Number of clusters 1145
p> χ2 < 0.001
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Treatment effectiveness
We assumed that the best eye in terms of visual acuity was always the first eye to be treated. We also
assumed that improvements in visual acuity in the best eye were not cumulative with the number of
treatments received and that the improvement would remain constant for the remainder of the simulation.
Effectiveness for diabetic maculopathy (M1)
To obtain estimates of treatment effectiveness of antiangiogenic therapy with anti-vascular endothelial
growth factor and laser photocoagulation we examined the Cochrane meta-analysis undertaken by
Virgili et al.91
For the model, we focused our attention on the results of the meta-analysis comparing antiangiogenic
therapy versus laser photocoagulation, with the outcome measured as difference in logMAR visual acuity
at 1 year. The 1-year effectiveness of photocoagulation was estimated at –0.016 (95% CI –0.048 to
0.0016) improvements in logMAR visual acuity. When antiangiogenic therapy was compared with laser
therapy the improvement in logMAR visual acuity at 1 year was –0.13 (95% CI –0.16 to –0.10).
Effectiveness for diabetic retinopathy (R2 and R3)
The annual probability of experiencing visual acuity loss for PDR and laser photocoagulation effectiveness
(in terms of relative rate of the probability of acuity losses given treatment) were obtained from the
modelling study by Rein et al.,90 which obtained these probabilities based on data from the Diabetic
Retinopathy Study and ETDRS.
Based on Rein et al.,90 we assumed the annual probability of experiencing visual acuity loss with no
treatment to be 0.141 (95% CI 0.127 to 0.155). Visual acuity loss was defined as a reduction of 18 letters
in logMAR visual charts, which corresponds to a change in logMAR visual acuity of +0.36. Therefore, the
annual mean logMAR visual acuity change, given no treatment, was 0.051 (95% CI 0.045 to 0.056).
TABLE 38 Predictors of treatment for DR or maculopathy: treatment received
Predictors Coefficient p> |z| 95% CI
Antiangiogenic therapy
True DR grade diagnosed at HES
R2–3M0 R0–1M0 Reference case
RxM1 RxM1 –0.228 0.682 –1.317 to 0.861
R2–3M0 R2–3M0 –3.142 < 0.001 –4.317 to –1.966
RxM1 RxM0 –1.174 0.032 –2.250 to –0.098
Constant 0.693 0.160 –0.274 to 1.660
Both antiangiogenic therapy and laser photocoagulation
True DR grade diagnosed at HES
R2–3M0 R0–1M0 Reference case
RxM1 RxM1 0.288 0.667 –1.022 to 1.597
R2–3M0 R2–3M0 –3.008 0.001 –4.843 to –1.174
RxM1 RxM0 –0.606 0.395 –2.002 to 0.789
Constant –0.693 0.259 –1.896 to 0.510
Number 310
Number of clusters 219
p> χ2 < 0.001
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Conversely, the annual mean logMAR visual acuity change, given photocoagulation treatment, was 0.021.
This was estimated by applying a relative of risk of 0.416 (95% CI 0.374 to 0.460).90 Therefore, the annual
change in logMAR visual acuity after laser photocoagulation was estimated at –0.030 (i.e. 0.021–0.051).
To assess the effectiveness of antiangiogenic therapy over laser photocoagulation we applied a risk ratio of
3.2 (95% CI 2.07 to 4.95). Therefore, logMAR visual acuity change after antiangiogenic therapy was
estimated at –0.095 (i.e. –0.30 × 3.2).
Monitoring by Hospital Eye Services if true state is R2–3 or M1
If diagnosis of grade 2/3 DR (R2–3) or diabetic maculopathy (M1) was confirmed in at least one eye in the
HES and patients were not treated, then, depending on clinical need, patients would either be monitored
by the HES every 6 months or referred back to the annual screening programme (Figure 16). Based on
clinical expert opinion, we assumed that 78% of patients not treated would be referred to be monitored
every 6 months. We tested this assumption and time interval for monitoring in the sensitivity analysis.
Life expectancy
2013 English national life tables for the general population were obtained,93 to which we applied the
relative risk of all-cause mortality in people with diabetes based on data from the Diabetes Epidemiology:
Collaborative Analysis of Diagnostic Criteria in Europe (DECODE) study.94
We did not apply any mortality decrement for visual loss, as data from the UKPDS95 found no significant
independent impact of blindness, in at least one eye, on all-cause mortality.
Health utility and quality-adjusted life expectancy
We identified a systematic literature review assessing the impact of visual acuity on health status utility
valuations in patients with DR, diabetic macular oedema or age-related macular degeneration.96
This review identified four studies assessing utility in patients with DR.
For the model we used the results from the study by Lloyd et al.,97 which assessed, using the European Quality
of Life-5 Dimensions (EQ-5D™), the utility associated with visual acuity (as measured using the logMAR scale in
the better seeing eye) in 49 patients with diabetes but no retinopathy and 122 patients with DR. The study
identified, through multiple regression, that age, disease-specific quality of life (as measured using the National
Eye Institute Visual Functioning Questionnaire) and visual acuity were all independent predictors of health utility.
To be able to use these estimates in the Markov model, we used the screening data from the Gloucestershire
Diabetic Eye Screening service to assess the association between logMAR visual acuity in the best eye and
DR/maculopathy grade observed at screening. For this, we performed an ordinary least squares regression
adjusting for DR/maculopathy grade, age and HbA1c and cholesterol levels at baseline (Table 39). The logMAR
visual acuity in the best eye by observed retinopathy grade was converted into logMAR in each true state using
the estimated error probabilities given in Table 25.
Health and social care resource use and costs
Screening costs
Costs of screening were obtained from 2009–10 NHS reference costs, which were then updated to
2012–13 prices, with a unit cost of £32 per person screened.98
In addition, we also performed a microcosting study, to assess the unit costs of screening to local programmes.
For this, a questionnaire was produced in which the local manager of a screening programme was asked to
provide information on the staff time and costs devoted to: administration; staff time for screening; equipment;
IT connections to upload, download and grade images; grading of images; and consumables. Using this
approach we found the unit cost of screening to be £33 per person screened. Given that the costs of screening
were virtually identical, we did not vary these estimates in one-way sensitivity analyses.
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Health-care resource use costs
Information on health-care costs was obtained from 17,043 people with diabetes from the Gloucestershire
Diabetic Eye Screening Service. For these patients, we obtained anonymised Hospital Episode Statistics
records. Hospital Episode Statistics provide details of all admissions and contacts in English hospitals
funded by the NHS, including information on:
1. admitted patient care: detailing all inpatient stays and day cases (including information on diagnoses,
procedures and length of stay)
2. adult critical care: detailing information on all stays in intensive treatment and critical care units,
including length of stay
3. renal care: detailing information of all the day cases in which patients underwent dialysis
4. outpatient care: detailing information on all outpatient contacts and specialties visited
5. accident and emergency care: detailing information on all accident and emergency contacts.
In England, NHS hospitals are reimbursed for the services they provide through a national tariff of prices
reflecting the national average cost of providing a hospital service. Each hospital service is assigned to
a Health Resource Group (HRG), which groups together similar clinical procedures that cost an equivalent
amount to deliver.99 Prices in the national tariff have been set on the basis of the average cost of providing
a particular HRG using data gathered from NHS hospitals. In addition, hospitals receive additional funding
for high-cost drugs, additional hospitalisation days past a certain threshold and provision of direct-access
diagnostics and specialised rehabilitation.
Each hospital contact was valued using the 2012–13 HRG English tariff. To determine the HRG for each
hospital contact, and any additional payments received for provision of additional services, each contact in
Hospital Episode Statistics was coded using the HRG grouper (version 4+ 2012–13) software (The Health
and Social Care Information Centre, Leeds, UK). HRGs were then linked to a series of elective, emergency
and procedure reference costs obtained from the 2012–13 schedule of NHS reference costs.100
TABLE 39 Predictors of logMAR visual acuity
Predictors Coefficient p> |z| 95% CI
Age 0.004 < 0.001 0.003 to 0.004
Observed DR grade at screening
R0M0 R0M0 Reference case
R1M0 R0M0 –0.006 < 0.001 –0.009 to –0.003
R1M0 R1M0 –0.005 0.009 –0.009 to –0.001
R2–3M0 R0–1M0 0.030 < 0.001 0.015 to 0.046
R2–3M0 R2–3M0 0.039 < 0.001 0.019 to 0.058
M1 M0 0.053 < 0.001 0.043 to 0.062
M1 M1 0.125 < 0.001 0.103 to 0.147
HbA1c < 0.001 < 0.001 0.000 to 0.001
Cholesterol 0.002 0.020 0.000 to 0.004
Constant –0.202 < 0.001 –0.222 to –0.182
Number 86,004
Number of clusters 14,963
p> χ2 < 0.001
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For each patient in the Gloucestershire Diabetic Eye Screening Service, information on health-care resource
use and costs obtained from Hospital Episode Statistics records was then linked with the information
collected as part of the screening programme. This included: date of screening; the grading of the retina
images; and the visual acuity as assessed using logMAR charts. Total costs were then evaluated on an
annual basis from the date of first screen, with each subsequent year being linked to the subsequent
screening rounds if they took place. Information from HES on referrals to the service, results of any
assessments for confirmation of diagnosis and treatment received by patients was also linked to Hospital
Episode Statistics and screening data. As before, these data were linked on annual basis from the date of
the first screen.
In total, we obtained cost and screening data for 17,043 patients, representing a total of 101,482 patient-years
(average of 5.95 years per patient). In 21,267 of these years (21%) screening did not occur. In these instances,
the results of the previous screen were carried forward (i.e. last value carried forward).
To assess the main predictors of total annual care costs, a generalised linear model (GLM) with a gamma
distribution, for the relationship between the variance and conditional mean, and a log link function,
clustered at the patient level, was performed. Predictors included observed DR and maculopathy grading
at screening; logMAR visual acuity as measured in the best seeing eye; whether the patient had attended
an assessment at HES; whether the patient had received treatment for DR or maculopathy (either laser
photocoagulation or antiangiogenic therapy); age; and HbA1c and cholesterol as measured at baseline
(i.e. shortly before the initial screen) (Table 40). The annual costs by observed retinopathy grade were
converted into costs by true retinopathy grade using the estimated error probabilities given in Table 25. An
advantage of including logMAR visual acuity in the best eye as a predictor of annual costs was that it
TABLE 40 Predictors of annual care costs after the initial DR screen
Predictors Coefficient Margins p> |z| 95% CI
Age 0.014 £17 < 0.001 14 to 19
DR grade observed at screening
R0M0 R0M0 Reference case
R1M0 R0M0 0.105 £112 0.001 £42 to £181
R1M0 R1M0 0.269 £310 < 0.001 £215 to £404
R2–3M0 R0–1M0 0.487 £629 < 0.001 £342 to £917
R2–3M0 R2–3M0 0.625 £871 < 0.001 £564 to £1,178
RxM1 RxM0 0.444 £560 < 0.001 £383 to £735
RxM1 RxM1 0.423 £528 < 0.001 £344 to £711
Assessment at HES 0.119 £134 0.005 £21 to £247
Treatment with
Photocoagulation 0.271 £307 0.005 £92 to £521
Antiangiogenic therapy 0.337 £382 < 0.001 £157 to £606
LogMAR visual acuity (best eye) 1.057 £1,197 < 0.001 £914 to £1,479
HbA1c 0.003 £4 0.001 £2 to £6
Cholesterol –0.044 –£50 < 0.001 –£79 to –£21
Constant 5.870
Number 86,004
Number of clusters 14,963
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allowed modelling of the impact of treatment not only in terms of utility but also costs. Furthermore, the
annual mean costs of assessment at the HES, £134 per patient assessed, and the annual mean costs of
treatment (£307 and £382 per patient treated with laser photocoagulation and antiangiogenic therapy,
respectively) were directly estimated using the GLM model.
Social care costs: nursing/residential care home admission
A targeted literature review was undertaken in MEDLINE to identify studies assessing nursing/residential
care home admission in patients with DR. The search was restricted to journals in the English language
published between January 1990 and June 2013. Search terms included variations of keywords for
retinopathy, diabetes, maculopathy, vision, visual loss, blind, institutionalisation, nursing home and
residential home. Citations of identified studies were also reviewed.
No study was identified that evaluated the risk of nursing/residential care home admission and DR. As a
result, we assessed studies evaluating the risk of nursing/residential care home admission and visual loss.
In total, 11 relevant studies were identified. For the model, we used the results from Evans et al.,101 which
evaluated the risk of nursing home admission in over 14,000 older people living in the community and
who were followed up for a mean of 4 years. The study found that after controlling for a number of
characteristics including age, sex, marital status, DM and other co-morbidities, the adjusted risk ratio of
being admitted was 1.14 (95% CI 0.97 and 1.34) for those with reduced vision (20/30 to 20/60) and 1.08
(95% CI 0.91 to 1.28) for those who were visually impaired (< 20/60) compared with those with good
vision (> 20/30) (5.4% risk of a nursing home admission after a mean of 4 years of follow-up; 382 out of
7010 cases).
To be able to use these estimates in the Markov model, we used the screening data from the Gloucestershire
Diabetic Eye Screening service to assess the probability of having good vision, reduced vision or visual
impairment, as defined by Evans et al.101 For this we performed an ordered logistic regression adjusting for
DR/maculopathy grade, age and HbA1c and cholesterol levels at baseline (Table 41). Given that over 95% of
TABLE 41 Predictors of visual loss category
Predictors Coefficient p> |z| 95% CI
Age 0.16 < 0.001 0.15 to 0.17
DR grade at screening
R0M0 R0M0 Reference case
R1M0 R0M0 –0.26 < 0.001 –0.36 to –0.16
R1M0 R1M0 –0.43 < 0.001 –0.56 to –0.31
R2–3M0 R0–1M0 0.33 0.042 0.01 to 0.65
R2–3M0 R2–3M0 0.12 < 0.001 –0.23 to 0.47
RxM1 RxM0 0.89 < 0.001 0.72 to 1.06
RxM1 RxM1 1.62 < 0.001 1.38 to 1.85
HbA1c 0.02 < 0.001 0.02 to 0.03
Cholesterol 0.02 0.563 –0.05 to 0.09
Cut: reduced vision 17.02 < 0.001 16.29 to 17.76
Cut: impaired vision 22.15 < 0.001 21.37 to 22.93
Number 86,004
Number of clusters 14,963
p> χ2 < 0.001
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residents living in nursing/residential care homes in the UK are aged 65 years and over,102 we assumed that
patients with diabetes would only be at risk of a nursing home admission if aged 65 years or older.
Furthermore, treatment for DR was assumed to shift all individuals with visual impairment to the reduced
vision group, and those with reduced vision to the good vision group. In sensitivity analysis, this assumption
was changed to: (1) shifting only 50% of cases from the worst to the better vision states; and (2)
improvement in vision only occurred for those with reduced vision.
The annual costs of institutionalisation in a care home were obtained from data published by the Personal
Social Services Research Unit,84 and estimated at £39,000 per year (£750 per week × 52 weeks).
Analysis
The value of £30,000 was adopted as the maximum willingness to pay for a QALY gained. The screening
interval was deemed to be cost-effective if the incremental cost-effectiveness ratio (ICER) was below this
threshold. Model internal validity was checked using sensitivity analysis (extreme values) and comparing
model outputs with the data used to build the model. Model comparison was performed by comparing the
results of our model with similar previous work.
Sensitivity and uncertainty analysis
Model parameters and structural assumptions were evaluated in one-way and probabilistic sensitivity
analysis. The distributions for the regression coefficients informing the several models described above
were obtained by bootstrapping the sample and re-estimating the regression models. This allowed the
correlation between coefficients to be captured fully. The joint distribution concerning the intensity matrix
between the seven retinopathy states was obtained by simulating from the maximum likelihood estimation
and hessian matrix of the parameters. The choice of distributions used for the remaining parameters was
made according to recommended practice.103
Relative effectiveness measures were modelled using a log-normal distribution. Incremental effectiveness
measures were modelled using normal distributions. Parameters concerning proportions/probabilities were
modelled using beta distributions. Coefficients of the regression model linking visual acuity and utility score
were assumed to be independent and normally distributed.89 Unit costs and resource use were modelled
using gamma distributions.
A cost-effectiveness acceptability curve (CEAC) was constructed104 and analysis of covariance methods
were used to determine the proportion of variance in the incremental costs and QALYs saved explained by
parameter uncertainty.103 Finally, the overall contribution of the model inputs to the decision uncertainty
was explored using the expected value of perfect information (EVPI). The EVPI per patient was estimated
non-parametrically.103
The EVPI for the total population who stand to benefit from reducing the decision uncertainty was also
estimated. This required information on the predicted lifetime of the screening technology and the period
over which information about the decision will be useful, T (5, 10 and 15 year scenarios), and the number
of diabetic patients eligible for screening in England (Pt):
EVPI for the population= EVPI∑Tt= 1P=(1þ r)t , (11)
where Pt was 2.2 million diabetic patients in England and the discount rate used (r), was 3.5%.
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Results
Diabetic retinopathy screening for patients with diabetes
Table 42 presents the baseline characteristics of the simulated cohort of 1000 people with diabetes. In this
cohort, 58% of patients had no DR in either eye, 23% had background retinopathy in one eye and a
further 19% had background retinopathy in two eyes.
For our simulated cohort, screening every 2, 3 and 5 years would result in a reduction of 5375 (95% CI
5332 to 5411), 7166 (95% CI 7111 to 7213) and 8617 (95% CI 8552 to 8672) screens, respectively,
compared with annual screening (Table 43). By screening every 2 years, as opposed to every year, a total
of 143 (95% CI 120 to 162) fewer patients incorrectly diagnosed at screening as having R2–3 or M1
(i.e. true negatives) would be referred to HES. These reductions in numbers increase to 190 (95% CI 159
to 215) and 229 (95% CI 191 to 259) when screening every 3 or 5 years, respectively.
By contrast, screening every 2 years, as opposed to annually, would reduce the number of patients with
true R2–3 or M1 grades (i.e. true positives) referred to HES, over the lifetime of the cohort, from 277 to
234 people, a reduction of 42 (95% CI 35 to 50) cases. Increasing the screening intervals to 3 years and
5 years would further reduce the number of true positives being referred by 74 (95% CI: 62 to 87) and 119
(95% CI: 100 to 139), respectively. This would result in 8 (95% CI 7 to 10), 15 (95% CI 12 to 17) and 25
TABLE 42 Baseline characteristics of the simulated cohort
True DR grade Patients
R0M0 R0M0, n (%) 580 (58)
R1M0 R0M0, n (%) 230 (23)
R1M0 R1M0, n (%) 190 (19)
Mean age, years 66.6
Sex: female, n (%) 440 (44)
Mean duration of diabetes, years 7.3
Mean cholesterol, mg/l 4.22
Mean HbA1c, mmol/mol 52.6
TABLE 43 Number of cases screened, referred, assessed and treated over the lifetime of a cohort of 1000 people
with diabetes
Outcomes
Screening every
6 months
Annual
screening
Screening every
2 years
Screening every
3 years
Screening every
5 years
Number of screens 21,990 11,253 5878 4087 2636
Number of patients referred following screening
True negatives 584 298 155 108 69
True positives 303 277 234 203 157
Number of patients assessed
by HES following screening
492 323 222 178 132
Number of patients treated
following screening
70 65 57 50 40
Number of patients treated
over lifetime
135 124 106 92 72
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(95% CI 21 to 29) fewer true cases of R2–3 or M1 being treated following screening if screening intervals
were to be extended to 2, 3 and 5 years, respectively, compared with annual screening (Table 43). Over a
lifetime, when compared with annual screening, there would be a reduction of 18 (95% CI 15 to 21), 32
(95% CI 27 to 37) and 52 (95% CI 44 to 59) true cases of R2–3 or M1 being treated if screening intervals
were to be extended to 2, 3 and 5 years, respectively.
With annual screening, the average discounted screening cost per patient was £273 for annual screening,
compared with £144, £101 and £67 for screening every 2, 3 and 5 years, respectively. Mean costs
associated with assessment at HES of referral of R2–3 or M1 suspected cases was also higher, at £114,
when screening annually than when screening at 2, 3 and 5 years (£70, £52 and £36, respectively), with a
similar pattern of costs being observed for treatment of R2–3 and M1. However, as the screening interval
increases, mean health-care costs (excluding screening, assessment and treatment) increase from £14,354
when screening every year to £14,377 at 2 years, £14,393 at 3 years and £14,413 at 5 years. Combining
all health and social care costs included in the model, mean discounted costs are £20,672 when screening
is performed annually, £20,490 when it is performed every 2 years, £20,433 when performed every 3
years, and £20,391 when performed every 5 years (Table 44). The discounted average QALYs gained by
patients were 8.3710 when screening every year, 8.3692 when screening every 2 years, 8.3680 when
screening every 3 years and 8.3663 when screening every 5 years.
After combining costs and outcomes in an incremental cost-effectiveness analysis, and at a £30,000
per QALY threshold, the most cost-effective screening interval was to screen patients every three years
(Table 45). The probability of screening every 3 years being the most cost-effective option at £30,000/
QALY was estimated to be 46%. Screening every 2 years was associated with an ICER of £45,684 per
QALY gained compared with screening every 3 years. Screening every 6 months was estimated to cost an
additional £288,497 per QALY gained compared with annual screening.
Figure 18 reports the CEAC and EVPI per patient associated with the different screening options. The
population EVPI over 5 years was estimated to be £86M at the £30,000 per QALY gained threshold.
This suggests that undertaking additional major commissioned research work to reduce further decision
uncertainty is likely to be of significant benefit given the large scale of the population affected by
the decision.
TABLE 44 Mean discounted costs and mean discounted outcomes of differing screening intervals
Costs and
outcomes
Screening every
5 years
Screening every
3 years
Screening every
two years
Annual
screening
Screening every
6 months
Total costs,
£ (95% CI)
20,391 (19,668
to 21,136)
20,433 (19,707
to 21,176)
20,490 (19,771
to 21,229)
20,672 (19,947
to 21,405)
21,050 (20,303
to 21,824)
Screening, £ 67 101 144 273 529
HES assessment, £ 36 52 70 114 193
Treatment of
R2–3 or M1, £
24 35 48 81 141
Other health-care
costs, £
14,413 14,393 14,377 14,354 14,337
Social care costs, £ 5852 5851 5851 5850 5850
Total QALYs
(95% CI)
8.3663 (4.3731
to 12.067)
8.3680 (4.3743
to 12.070)
8.3692 (4.3753
to 12.071)
8.3710 (4.3768
to 12.074)
8.3723 (4.3779
to 12.0755)
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Figure 19 reports the parameters according to their impact on the variance of incremental costs and QALYs
from the comparison of screening every 3 years with every 5 years. Variance in the estimated incremental
costs was dominated by the variation in the following variables: costs of assessment following referral to
HES; treatment costs; hospital costs; and effectiveness inputs. Variance in the incremental QALYs was
dominated by the variance in the regression model associating utility with visual acuity, effectiveness inputs
(mostly the effectiveness of laser/injection for M1) and natural history of progression.
Table 46 reports the results of a range of other sensitivity analyses. Changes in the monitoring interval by
HES from 6 months to 12 months did not alter the decision. The results were also robust to the proportion
of individuals with M1 or R2–R3 that are referred to further monitoring every 6 months if assessed by
HES but not treated. Given the difference in effectiveness across treatments, depending on which type of
treatment was received there was a significant impact on the results. For example, increasing the proportion
of M1 cases receiving injection rather than laser treatment among those treated resulted in screening every
2 years falling under the £30,000 per QALY threshold.
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FIGURE 18 Cost-effectiveness acceptability curve and EVPI per patient.
TABLE 45 Cost-effectiveness of differing screening intervals
Screening
strategies
Difference in costs,
£ (95% CI)
Difference in QALYs
(95% CI) ICER, £
Probability that intervention
is the most cost-effective at
£30,000/QALY, %
Every 5 years – – – 41
Every 3 years 42 (26 to 58) 0.0019 (0.0004 to 0.0029) 26,156 46
Every 2 years 57 (41 to 73) 0.0012 (0.0003 to 0.0023) 45,684 13
Annually 182 (141 to 226) 0.0018 (0.0005 to 0.0034) 98,085 0
Every 6 months 378 (306 to 457) 0.0013 (0.0003 to 0.0024) 288,497 0
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TABLE 46 Sensitivity analysis scenarios: impact of differing assumptions on ICERs
Sensitivity analysis scenarios
Screening every 3 years vs.
every 5 years
Screening every 2 years vs.
every 3 years
Base case £26,156 £45,684
Screening uptake: 81% £27,060 £47,805
Screening uptake: 91% £31,175 £56,503
Screening uptake: 71% £23,305 £40,008
Hospital costs only (excluding social care costs) £26,724 £46,582
50% shift from visual impairment to reduced vision
and from reduced vision to good vision
(affects nursing home admission)
£26,296 £46,194
Only cases with reduced vision shift to good vision
(affects nursing home admission)
£26,644 £46,495
Proportion of M1 cases treated with injection
rather than laser: increase of 30%
£16,515 £31,403
All M1 cases are treated with injection or
a combination of laser and injection
£12,438 £24,624
Probability of being referred to monitoring every
6 months of 0% instead of 78%
£29,796 £45,566
Probability of being referred to monitoring every
6 months of 50% instead of 78%
£26,539 £44,520
Probability of being referred to monitoring every
6 months of 100% instead of 78%
£25,880 £47,635
Monitoring interval by HES of 12 months instead
of 6 months if R2–3 or M1
£25,709 £45,117
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FIGURE 19 Analysis of covariance analysis of proportion of sum of squares for incremental QALYs saved and
incremental costs explained by the uncertainty in the model inputs.
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Cost-effectiveness of differing screening intervals by risk group as defined
from the results from two consecutive screening episodes
We further assessed the cost-effectiveness of the different DR screening intervals in three groups at
differing risks of developing R2–3 or M1 as defined in Table 33.
For the low-risk group (i.e. patients with no DR in either eye in two SEs), mean costs associated with
assessment at HES of referral of R2–3 or M1 suspected cases was higher (£46) when screening annually
than when screening at 2, 3 and 5 years (£27, £20 and £13, respectively), with a similar pattern of costs
being observed for treatment of R2–3 and M1. However, as the screening interval increases, other
health-care costs increase slightly from £13,378 when screening every year to £13,387 at 2 years, £13,392
at 3 years and £13,999 at 5 years. Combining all health and social care costs included in the model, mean
discounted costs are £19,586 when screening is performed annually, £19,434 when performed every
2 years, £19,385 when performed every 3 years, and £19,346 when performed every 5 years (Table 47).
The discounted average QALYs gained by patients were 8.3558 when screening every year, 8.3551 when
screening every 2 years, 8.3547 when screening every 3 years and 8.3541 when screening every 5 years.
The most cost-effective screening intervention for the low-risk group was screening every 5 years (Table 48),
with a probability of being the most cost-effective intervention of 99% at the £30,000 per QALY threshold.
Other screening intervals for this patient group yielded considerably higher ICERs. For example, when
screening every 3 years was compared with screening every 5 years the associated ICER was above £72,000
per QALY gained.
For the medium-risk group (i.e. patients with background DR in one eye in two SEs), mean discounted
costs were £21,180 when screening is performed annually, £20,992 when performed every 2 years,
£20,933 when performed every 3 years, and £20,892 when performed every 5 years (Table 49). The
discounted average QALYs gained by patients were 8.3314 when screening every year, 8.3292 when
screening every 2 years, 8.3277 when screening every 3 years and 8.3258 when screening every 5 years.
TABLE 47 Mean discounted costs and mean discounted outcomes of differing screening intervals in low-risk
patients (two consecutive SEs)
Costs and
outcomes
Screening every
5 years
Screening every
3 years
Screening every
2 years
Annual
screening
Screening every
6 months
Total costs,
£ (95% CI)
19,346 (18,714
to 20,018)
19,385 (18,754
to 20,055)
19,434 (18,805
to 20,103)
19,586 (18,960
to 20,259)
19,894 (19,253
to 20,572)
Screening, £ 67 102 145 275 535
HES
assessment, £
13 20 27 46 81
Treatment of
R2–3 or M1, £
8 12 16 28 48
Other health-care
costs, £
13,399 13,392 13,387 13,378 13,372
Social care
costs, £
5864 5864 5863 5863 5863
Total QALYs
(95% CI)
8.3541 (4.6933
to 12.2316)
8.3547 (4.6940
to 12.2320)
8.3551 (4.6945
to 12.2323)
8.3558 (4.6952
to 12.2327)
8.3563 (4.6958
to 12.2331)
PHASE 4: COST-EFFECTIVENESS OF DIFFERING SCREENING INTERVALS IN DIABETIC RETINOPATHY SCREENING
NIHR Journals Library www.journalslibrary.nihr.ac.uk
72
For the medium-risk group the most cost-effective screening intervention was screening every 3 years
(Table 50). When screening for DR every 3 years was compared with screening every 5 years, the
incremental cost per QALY gained was £22,266. By contrast, when screening for DR every 2 years was
compared with screening every 3 years, the incremental cost per QALY gained was £39,829, with the
probability of screening every 2 years being the most cost-effective at 25%.
Of all the three risk groups assessed, high-risk patients (i.e. patients with background retinopathy in both eyes)
had the highest mean discounted health and social care costs, regardless of screening strategy implemented.
Mean discounted costs were £25,043 when screening is performed annually, £24,734 when performed every
2 years, £24,649 when performed every 3 years, and £24,600 when performed every 5 years (Table 51).
The discounted average QALYs gained by patients were 9.2691 when screening every year, 9.2620 when
screening every 2 years, 9.2570 when screening every 3 years and 9.2503 when screening annually.
For the high-risk group the most cost-effective screening intervention was screening every 2 years (Table 52).
When screening for DR every 2 years was compared with screening every 3 years, the incremental cost
per QALY gained was £16,926. The probability of screening every 2 years being the most cost-effective
intervention was 59%. By contrast, when annual screening for DR was compared with screening every
2 years, the incremental cost per QALY gained was £43,156, with a probability of annual screening being
the most cost-effective intervention of 21%.
TABLE 49 Mean discounted costs and mean discounted outcomes of differing screening intervals in medium-risk
patients (two consecutive SEs)
Costs and
outcomes
Screening every
5 years
Screening every
3 years
Screening every
2 years
Annual
screening
Screening every
6 months
Total costs,
£ (95% CI)
20,892 (20,156
to 21,674)
20,933 (20,201
to 21,722)
20,992 (20,253
to 21,786)
21,180 (20,415
to 21,990)
£21,573 (20,784
to 22,378)
Screening, £ 67 101 144 272 526
HES assessment, £ 41 60 80 131 221
Treatment of R2–3
or M1, £
27 41 55 93 162
Other health-care
costs, £
14,905 14,880 14,861 14,833 14,812
Social care costs, £ 5856 5856 5855 5855 5,854
Total QALYs
(95% CI)
8.3258 (4.6654
to 12.1034)
8.3277 (4.6680
to 12.1062)
8.3292 (4.6700
to 12.1083)
8.3314 (4.6731
to 12.1116)
8.3329 (4.6754
to 12.1138)
TABLE 48 Cost-effectiveness of differing screening intervals in low-risk patients (two consecutive SEs)
Screening
strategies
Difference in costs,
£ (95% CI)
Difference in QALYs
(95% CI) ICER, £
Probability that intervention
is the most cost-effective at
£30,000/QALY, %
Every 5 years – – – 99
Every 3 years 39 (32 to 46) 0.0005 (0.0001 to 0.0010) 72,217 1
Every 2 years 49 (42 to 57) 0.0004 (0.0001 to 0.0008) 113,823 0
Annually 152 (131 to 171) 0.0007 (0.0002 to 0.0013) 225,004 0
Every 6 months 308 (279 to 344) 0.0005 (0.0001 to 0.0010) 615,664 0
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TABLE 51 Mean discounted costs and mean discounted outcomes of differing screening intervals in high-risk
patients (two consecutive SEs)
Costs and
outcomes
Screening every
5 years
Screening every
3 years
Screening every
2 years
Annual
screening
Screening every
6 months
Total costs,
£ (95% CI)
24,600 (23,578
to 25,665)
24,649 (23,633
to 25,710)
24,734 (23,711
to 25,793)
25,043 (23,991
to 26,147)
25,728 (24,586
to 26,934)
Screening, £ 71 107 152 286 551
HES
assessment, £
129 185 242 384 635
Treatment of
R2/3 or M1, £
96 142 191 321 557
Other health-care
costs, £
18,779 18,691 18,626 18,531 18,465
Social care costs, £ 5525 5523 5522 5521 5520
Total QALYs
(95% CI)
9.2503 (5.4153
to 13.3784)
9.2570 (5.4241
to 13.3874)
9.2620 (5.4308
to 13.3939)
9.2691 (5.4408
to 13.4034)
9.2740 (5.4480
to 13.4074)
TABLE 50 Cost-effectiveness of differing screening intervals in medium-risk patients (two consecutive SEs)
Screening
strategies
Difference in costs,
£ (95% CI)
Difference in QALYs
(95% CI) ICER, £
Probability that intervention
is the most cost-effective at
£30,000/QALY, %
Every 5 years – – – 31
Every 3 years 42 (22 to 60) 0.0019 (0.0003 to 0.0036) 22,266 43
Every 2 years 58 (38 to 77) 0.0015 (0.0003 to 0.0028) 39,829 25
Annually 188 (139 to 236) 0.0022 (0.0004 to 0.0042) 86,614 0
Every 6 months 394 (307 to 479) 0.0015 (0.0003 to 0.0030) 256,354 0
TABLE 52 Cost-effectiveness of differing screening intervals in high-risk patients (two consecutive SEs)
Screening
strategies
Difference in costs,
£ (95% CI)
Difference in QALYs
(95% CI) ICER, £
Probability that intervention
is the most cost-effective at
£30,000/QALY, %
Every 5 years – – – 3
Every 3 years 49 (–6 to 109) 0.0067 (0.0016 to 0.0127) 7197 16
Every 2 years 84 (32 to 144) 0.0050 (0.0012 to 0.0095) 16,962 59
Annually 309 (180 to 457) 0.0071 (0.0017 to 0.0136) 43,156 21
Every 6 months 685 (451 to 942) 0.0049 (0.0009 to 0.0094) 139,921 0
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Cost-effectiveness of differing screening intervals by risk group as defined
from the results of the initial screening episode and baseline clinical
risk factors
We assessed the cost-effectiveness of the different DR screening intervals in four groups at differing risks
of developing R2–3 or M1 conditional on baseline CRFs (Table 33).
For the low-risk group, mean costs associated with assessment at HES of referral of R2–3 or M1 suspected
cases were higher (£35) when screening annually than when screening at 2, 3 and 5 years (£20, £15 and
£10, respectively), with a similar pattern of costs being observed for treatment of R2–3 and M1. However, as
the screening interval increases, other health-care costs increase slightly from £13,349 when screening every
year to £13,354 at screening every 2 years, £13,358 at 3 years and £13,363 at 5 years. Combining all health
and social care costs included in the model, mean discounted costs are £19,537 when screening is performed
annually, £19,381 when performed every 2 years, £19,330 when performed every 3 years, and £19,290
when performed every 5 years (Table 53). The discounted average QALYs gained by patients were 9.0488
when screening every year, 9.0484 when screening every 2 years, 9.0480 when screening every 3 years and
9.0476 when screening every 5 years.
The most cost-effective screening intervention for the low-risk group was screening every 5 years (Table 54),
with a probability of being the most cost-effective intervention of 100% at the £30,000 per QALY
threshold. Other screening intervals for this patient group yielded considerably higher ICERs. For example,
when screening every 3 years was compared with screening every 5 years, the associated ICER was above
£90,000 per QALY gained.
For the low- to medium-risk group, mean discounted costs were £21,194 when screening is performed
annually, £21,004 when performed every 2 years, £20,946 when performed every 3 years, and £20,904
when performed every 5 years (Table 55). The discounted average QALYs gained by patients were 9.2588
when screening every year, 9.2569 when screening every two years, 9.2555 when screening every three
years and 9.2538 when screening every 5 years.
TABLE 53 Mean discounted costs and mean discounted outcomes of differing screening intervals in low-risk
patients (one SE+CRF)
Costs and
outcomes
Screening every
5 years
Screening every
3 years
Screening every
2 years
Annual
screening
Screening every
6 months
Total costs,
£ (95% CI)
19,290 (18,623
to 20,018)
19,330 (18,663
to 20,057)
19,381 (18,715
to 20,108)
19,537 (18,875
to 20,265)
19,854 (19,186
to 20,582)
Screening, £ 71 108 154 293 571
HES assessment, £ 10 15 20 35 61
Treatment of
R2/3 or M1, £
6 9 12 21 37
Other health-care
costs, £
13,363 13,358 13,354 13,349 13,344
Social care costs, £ 5840 5840 5840 5840 5840
Total QALYs
(95% CI)
9.0476 (5.0056
to 13.0951)
9.0480 (5.0062
to 13.0955)
9.0484 (5.0067
to 13.0959)
9.0488 (5.0074
to 13.0965)
9.0492 (5.0079
to 13.0968)
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The most cost-effective screening intervention for the low- to medium-risk group was screening every
3 years (Table 56), with an ICER of £23,893 per QALY gained when compared with screening every 5 years.
The probability that screening every 3 years was the most cost-effective intervention was 48% at a £30,000
per QALY threshold.
For the medium- to high-risk group, mean discounted costs were £22,525 when screening is performed
annually, £22,288 when performed every 2 years, £22,218 when performed every 3 years, and £22,173
when performed every 5 years (Table 57). The discounted average QALYs gained by patients were 9.3956
when screening every year, 9.3919 when screening every 2 years, 9.3893 when screening every 3 years
and 9.3857 when screening every 5 years.
For the medium- to high-risk group, the most cost-effective screening intervention was screening every
2 years (Table 58), which was associated with an ICER of £26,406 per QALY gained when compared
with screening every 3 years. The probability that screening every 2 years was the most cost-effective
intervention was 57% at a £30,000 per QALY threshold.
TABLE 55 Mean discounted costs and mean discounted outcomes of differing screening intervals in low- to
medium-risk patients (one SE+CRF)
Costs and
outcomes
Screening every
5 years
Screening every
3 years
Screening every
2 years
Annual
screening
Screening every
6 months
Total costs,
£ (95% CI)
20,904 (20,218
to 21,629)
20,946 (20,257
to 21,677)
21,004 (20,316
to 21,738)
21,194 (20,474
to 21,938)
21,590 (20,826
to 22,344)
Screening, £ 71 108 154 293 569
HES assessment, £ 34 51 68 118 190
Treatment of
R2/3 or M1, £
24 36 49 83 145
Other health-care
costs, £
15,253 15,230 15,214 15,189 15,171
Social care costs, £ 5521 5521 5520 5520 5520
Total QALYs
(95%)
9.2538 (5.2104
to 13.5974)
9.2555 (5.2121
to 13.5980)
9.2569 (5.2133
to 13.5984)
9.2588 (5.2151
to 13.5991)
9.2602 (5.2163
to 13.5996)
TABLE 54 Cost-effectiveness of differing screening intervals in low-risk patients (one SE+CRF)
Screening
strategies
Difference in costs,
£ (95% CI)
Difference in QALYs
(95% CI) ICER, £
Probability that intervention
is the most cost-effective at
£30,000/QALY, %
Every 5 years – – – 100
Every 3 years 40 (35 to 45) 0.0004 (0.0001 to 0.0008) 97,059 0
Every 2 years 51 (46 to 56) 0.0003 (0.0001 to 0.0006) 158,008 0
Annually 156 (144 to 169) 0.0005 (0.0001 to 0.0010) 324,774 0
Every 6 months 316 (293 to 341) 0.0003 (0.0001 to 0.0007) 930,079 0
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TABLE 56 Cost-effectiveness of differing screening intervals in low- to medium-risk patients (one SE+CRF)
Screening
strategies
Difference in costs,
£ (95% CI)
Difference in QALYs
(95% CI) ICER, £
Probability that intervention
is the most cost-effective at
£30,000/QALY, %
Every 5 years – – – 35
Every 3 years 42 (26 to 59) 0.0018 (0.0004 to 0.0035) 23,893 48
Every 2 years 58 (42 to 76) 0.0014 (0.0003 to 0.0027) 43,597 17
Annually 189 (150 to 233) 0.0020 (0.0004 to 0.0039) 96,556 0
Every 6 months 396 (326 to 475) 0.0014 (0.0003 to 0.0027) 289,293 0
TABLE 57 Mean discounted costs and mean discounted outcomes of differing screening intervals in medium- to
high-risk patients (one SE+CRF)
Costs and
outcomes
Screening every
5 years
Screening every
3 years
Screening every
2 years
Annual
screening
Screening every
6 months
Total costs, £ 22,173 22,218 22,288 22,525 23,036
Screening, £ 71 108 153 290 563
HES assessment, £ 71 101 133 212 354
Treatment of
R2/3 or M1, £
52 77 104 175 304
Other health-care
costs, £
16,447 16,402 16,368 16,319 16,286
Social care costs, £ 5532 5530 5530 5529 5529
Total QALYs
(95% CI)
9.3857 (5.4478
to 13.7326)
9.3893 (5.4541
to 13.7339)
9.3919 (5.4586
to 13.7350)
9.3956 (5.4649
to 13.7364)
9.3982 (5.4691
to 13.7374)
TABLE 58 Cost-effectiveness of differing screening intervals in medium- to high-risk patients (one SE+CRF)
Screening
strategies
Difference in costs,
£ (95% CI)
Difference in QALYs
(95% CI) ICER, £
Probability that intervention
is the most cost-effective at
£30,000/QALY, %
Every 5 years – – – 10
Every 3 years 46 (14 to 76) 0.0037 (0.0009 to 0.0069) 12,823 30
Every 2 years 69 (38 to 100) 0.0027 (0.0006 to 0.0051) 26,406 57
Annually 238 (160 to 314) 0.0039 (0.0009 to 0.0073) 63,421 3
Every 6 months 511 (375 to 647) 0.0026 (0.0006 to 0.0050) 201,870 0
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For the high-risk group, mean discounted costs were £26,212 when screening is performed annually,
£25,863 when performed every 2 years, £25,773 when performed every 3 years, and £25,730 when
performed every 5 years (Table 59). The discounted average QALYs gained by patients were 10.2733
when screening every year, 10.2637 when screening every two years, 10.2570 when screening every
three years and 10.2477 when screening every 5 years.
As with the two screening risk stratification model, screening patients deemed to be at high risk every
2 years was the most cost-effective screening intervention (Table 60). For this group of patients, screening
every 2 years was associated with an ICER of £13,302 per QALY gained compared with screening every
3 years, and the probability that screening every 2 years was the most cost-effective intervention was 55%.
Annual screening was associated with an ICER of £36,364 per QALY gained compared with screening
every 2 years, with a probability of annual screening being cost-effective of 34%.
TABLE 60 Cost-effectiveness of differing screening intervals in high-risk patients (one SE+CRF)
Screening
strategies
Difference in costs,
£ (95% CI) Difference in QALYs (95% CI) ICER, £
Probability that
intervention is the
most cost-effective
at £30,000/QALY, %
Every 5 years – – – 2
Every 3 years 43 (–36 to 125) 0.0093 (0.0021 to 0.0170) 4620 9
Every 2 years 89 (12 to 168) 0.0068 (0.0016 to 0.0124) 13,302 55
Annually 349 (166 to 542) 0.0096 (0.0022 to 0.0177) 36,364 34
Every 6 months 792 (469 to 1120) 0.0066 (0.0014 to 0.0121) 120,605 0
TABLE 59 Mean discounted costs and mean discounted outcomes of differing screening intervals in the high-risk
group (one SE+CRF)
Costs and
outcomes
Screening every
5 years
Screening every
3 years
Screening every
2 years
Annual
screening
Screening every
6 months
Total costs, £ 25,730 25,773 25,863 26,212 27,003
Screening, £ 73 112 159 300 579
HES assessment, £ 162 232 303 478 786
Treatment of
R2/3 or M1, £
121 181 244 408 705
Other health-care
costs, £
20,620 20,498 20,409 20,280 20,187
Social care costs, £ 4752 4749 4747 4746 4745
Total QALYs
(95% CI)
10.2477 (5.6241
to 14.7498)
10.2570 (5.6345
to 14.7557)
10.2637 (5.6422
to 14.7599)
10.2733 (5.6535
to 14.7659)
10.2799 (5.6616
to 14.7700)
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Conclusion
Diabetic retinopathy screening is widely recommended and has shown to be cost-effective compared with
no screening.9,10,12 However, a less clear understanding exists on the most appropriate screening interval,
with published cost-effectiveness evidence showing conflicting results.48
Our cost-effectiveness analysis shows that for patients with diabetes and no pre-proliferative DR or PDR or
maculopathy, the current national screening programme of screening patients annually is not cost-effective.
Results from our study show that for this group of patients, screening every 3 years would be the most
cost-effective option. Annual screening, by contrast, was associated with an incremental cost-effectiveness
ratio of £98,085 compared with the next less effective DR screening strategy (i.e. screening every 2 years).
At current NICE thresholds of £20,000 to £30,000 per QALY gained, annual screening would not be
considered cost-effective. Our results are similar to those by Brailsford et al.,88 which concluded that a
30-month screening interval was the most cost-effective option.
Irrespective of how patients were stratified in terms of their risk of developing STDR/maculopathy, our
results suggest that the cost-effectiveness of the screening programme could be further improved by
targeting patients using differing intervals for patients at different risks of developing STDR/maculopathy.
Stratifying both based on the results from two consecutive SEs or based on the first single SE in
conjunction with CRF data produced very similar results. In both risk stratification models, screening
patients at low risk every 5 years, and those at high risk every 2 years would be the most cost-effective DR
screening strategy.
There is, however, considerable uncertainty in the evidence informing the model, particularly the natural
history of disease progression, association between utility scores and visual acuity and the effectiveness of
treatment in diabetic maculopathy. There is also considerable uncertainty concerning the annual marginal
costs attributable to treatment and assessments in the HES. This is reflected in the very large EVPI values of
£86M to £458M, conditional on the expected lifetime of the current technology for screening. The EVPI
gives the maximum amount of funding required for further research to reduce the decision uncertainty
about which of the screening intervals is the most cost-effective option. The large population of diabetic
patients that will be affected by making the wrong decision, together with considerable uncertainty in the
evidence available, warrant caution about the model results. Hence, our results suggest undertaking
additional major commissioned research work to further reduce the decision uncertainty.
There are several limitations to consider. First, there was very limited information concerning the proportion
of patients with R2–3 or M1 grade that are referred for further monitoring by the HES. This led to
assumptions being made concerning both the interval of monitoring and the proportion of patients being
referred to it. However, sensitivity analyses showed the model results to be fairly robust to variations in these
assumptions. The small number of patients in these health states also prevented the separation of R2 and
R3 states. Hence, pre-proliferative and proliferative retinopathy were grouped together as both are grades
prompting referral to the HES and are sight-threatening states. The absorbing states used, R2/R3 M0 and Rx
M1 in both eyes, meant that no onwards state progression was explicitly modelled between and from these.
However, such states lead to treatment, which seems to have limited effect on the retinopathy grade91 and,
therefore, disease progression was implicitly modelled in terms of costs, visual acuity and utilities, which
were found to increase with age/duration of diabetes. Furthermore, the lack of movements between the
absorbing states is likely to have limited impact as few patients were identified as making such a transition.
Second, owing to the cohort nature of the model and the focus on simulating the progression of true states,
it was not possible to evaluate strategies based on which states were observed at consecutive screening
rounds. An alternative would have been to analyse the Markov model as an individual-based model
(i.e. microsimulation) so that we could keep track of each individual’s history.105 This would have allowed
tailoring the frequency of screening during the lifetime of a cohort of patients conditional on the
observed grades.
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Although a great proportion of the data used were derived from patient-level data in patients with
diabetes, we were not able to obtain all model parameters from this group of patients and, therefore, we
had to obtain some of the model parameters from the literature. These included the risk of nursing home
admission given losses in vision, health state utility values, and treatment effectiveness. As a result, the
populations on which these studies based their results might be different from those in which the majority
of the data were obtained (i.e. those attending the Gloucestershire DESP). For example, the data on the
effectiveness of laser photocoagulation for treatment of STDR were obtained from evidence from the
1980s and early 1990s. In addition, the results are conditional on the model structure and the evidence
used to inform it. For example, we used the results from the study by Lloyd et al.,97 which assessed, using
the EQ-5D, the utility associated with visual acuity. However, as with the other three studies identified,
this association was only available for the best eye (in terms of visual acuity). Therefore, for modelling
purposes, we assumed that the best seeing-eye was always the first to be treated. Internal validity was
performed and was complemented by the exploration of different parameter and structural scenarios in
the sensitivity analysis.
Routinely collected data were used to assess the impact of DR grade and visual acuity on health-care
resource usage and costs. Therefore, it was not possible to determine whether use of health-care services
was directly a result of vision loss or whether it was a result of other diabetes-related complications
(such as stroke or heart attacks), given that poorly controlled diabetes is associated with both vision loss
and other diabetes-related complications.95 We performed additional analyses to assess whether the
association between DR grade/visual acuity and annual care costs was confounded. Using the diagnoses
codes included in patients’ HES records, we were able to estimate patients’ Charlson Co-morbidity Index
(CCI) based on 22 clinical conditions present within a patient (including myocardial infarction, stroke,
acquired immunodeficiency syndrome and tumours).106 When we adjusted for CCI, the significant and
positive association between DR grade/visual acuity and annual care costs was still observed.
Finally, our analysis is from the perspective of the NHS and personal social services. As a result, other
important cost categories not relevant to the perspective adopted were not included in the analysis.
For example, we excluded some important economic considerations for people with visual loss, such as
reductions in earnings through reduced or lost productivity, and the economic consequences of reduced
mobility associated with vision loss (for example, people with moderate vision loss not being able to drive).
In conclusion, the work presented here suggests that it may be good value for money to use differing
intervals for patients at different risks of developing STDR/maculopathy. Further research is needed to
make more informed decisions.
PHASE 4: COST-EFFECTIVENESS OF DIFFERING SCREENING INTERVALS IN DIABETIC RETINOPATHY SCREENING
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Chapter 9 Other research using the same data set
1. This data set was used to demonstrate that the rate of detection of referable DR is elevated in those
who were not screened promptly after diagnosis of type 2 diabetes.107
2. The data set was also used to compare characteristics of those newly diagnosed with type 2 diabetes
between 2005 and 2012 with those recruited to UKPDS (1978–90). Patients in this screening
programme have less DR and less referable DR and are less hyperglycaemic, more hypertensive and
heavier than those newly diagnosed patients recruited to UKPDS.
Data were available for 2070 men and 1375 women, of whom 1403 (68%) men and 990 (72%) women
had no retinopathy. Of those with DR, 20% had microaneurysms in one eye, 9% had microaneurysms in
both eyes and 2% had referable retinopathy, and there was more retinopathy in men than in women
(p-value= 0.0033). Patients were of similar ages to those in UKPDS and had lower HbA1c (mean difference
–1.8%, –20mmol/mol), higher systolic and diastolic blood pressure (+7 mmHg and +2mmHg) and higher
BMI (+4 kg/m2). Proportionately more participants in UKPDS had any DR (39% of men and 34% of women)
and more had referable DR (15% of men and 11% of women, p-value < 0.0001).
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Chapter 10 Lay perspective
Mike Whatmore’s contribution
I have been an independent member of the HTA Trial Steering Committee from its inception in October
2012, and actively involved at both live meetings and updated with all necessary interim documents by
e-mail. Also, during this first meeting, a presentation was made of the data set information to be used for
all areas involved in the study, and classification for reference for diabetic retinopathy.
In November 2012, I received an e-mail with the HTA Interim Progress Report attached, which included
details of how the studies had been carried out to date and how problems encountered with the lack of
data from one of the original expected sources, in South London, had been overcome and an alternative
set of appropriate data had been accessed from the Nottingham Screening Service team.
At the second, live meeting, on 31 March 2014, the latest data obtained was presented, showing that
progress was continuing to be made, and indicating the potential for considerations to be made to the
current screening intervals. I made comments about showing the practical use of extending the screening
intervals, and stated that I thought any changes would require good communication between all affected
parties, viz. the Screening Service and G.P.’s, and, the G.P. and patient; supporting the reasons for making
any changes to the current screening interval with accurate, precise results and providing examples to
reinforce the justification.
In November 2014, I received a draft copy of the proposed HTA ‘Final’ Report, which asked for any
comments I may wish to make, and I pointed out some minor errors within the text of the document.
I have read and understood the majority of the details contained in the Final Report (some of the statistical
documentation, in chapter 5, I found confusing and did not fully understand) and accept the suggested
recommendations to amend the intervals for diabetic eye screening. I would hope that monitoring of these
changes, if applied, continues in the future and further safe, practical, outcomes are acted upon.
Mike Larkin’s contribution
Mike Larkin has met with the Lead Researcher regularly during the period of this research.
To date, my input has been reading and reviewing the drafts and providing a perspective on the work.
I think my feedback covers two distinct areas:
l Feedback on the report as a lay reader – here I have suggested a different plain English summary
that attempts to take out the obvious and simplify the kernel of the research to help other
non-researchers understand the project.
l Patient view on the benefits of extending screening intervals. In a free to use system, patients don’t
necessarily see benefit in less access. My comments are intended to acknowledge this and should
be part of future discussion.
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I think that overall the report moves a great way to better understanding suitable screening intervals –
something that will be essential in the forthcoming years as we look to address the Type 2 epidemic.
l Whilst there is acknowledgement that Type 1 patients are likely to receive closer monitoring
(from the risk factor regarding length of condition) it’s dangerous to assume that both types of
diabetes will affect the eyes the same. I feel that Type 1 as a condition is far more aggressive than
Type 2 (for the same period of time). HbA1c levels are certainly good indicators for long term
control, but are by their nature, averages. They don’t show if a person has had extreme highs over
the 3 month period that the test is measuring. It’s for this reason that condition type should be
differentiated in any recommendations on screening interval.
l The reference to the lack of evidence around economic consequences of visual loss to the patient
is important. It would be useful if this area could be considered in more depth. Before a person is
able to officially register sight impairment, productivity and quality of life will, I believe, already
have been significantly impacted. From a personal perspective, losing my sight to a point when I
can no longer drive would have a substantial impact as mobility at home and work is restricted.
Whilst, from a clinical sense, a person may have acceptable vision, the lack of personal mobility is
economically and emotionally dramatic. The report sections centred on economics has focused
entirely upon the costs to the NHS and not attributed any value to individual reduction
of productivity.
LAY PERSPECTIVE
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Chapter 11 Conclusions
This project has demonstrated that:
1. Risk stratification can be used to identify low-risk groups. Risk estimation using either one SE plus
clinical information or data from two sequential SEs in this quality-assured Gloucestershire programme
are equally powerful for categorising risk. The risk model developed using results from one SE plus
clinical information was then validated in three English screening programmes, two of which had a
higher prevalence of people from ethnic minorities.
2. The model used in this study aimed to determine the risk of referable DR, which included the risk of
developing maculopathy as well as the risk of development of pre-proliferative DR or PDR. The risk
factors that were included in the model were duration of diabetes and HbA1c. Type of diabetes was
not included because it could not be separated from duration of diabetes and HbA1c. Other risk factors
that were considered but not included in the model because they did not have a significant impact
were systolic and diastolic blood pressure, smoking status, sex, BMI, serum creatinine, total cholesterol,
urine albumin and albumin : creatinine ratio.
3. Misclassification of a photograph to a more advanced stage (FP result) is more common than
misclassification into a lower grade (FN result). The probability of misclassifying a photograph as a
referable level from all lower grades is very small but this may be more reflective of the limitations of
the method used.
4. A modelling approach to estimate misclassification rates is feasible using data from a screening
programme but may be limited to progression up to, but no further than, referral.
5. The algorithms and approach developed in this project would be useful when deciding which of the
local programmes should pilot and be early implementers of trialled risk-based extended screening
intervals and which programmes need to look more closely at the grading of mild retinopathy before
extension of screening intervals is considered. This should assist in reducing data variation
between centres.
6. For all patients with diabetes and no presence of STDR, screening every 3 years was found to be the
most cost-effective strategy using data from Gloucestershire.
7. Using a risk-based strategy, screening those at medium and high risk of developing STDR/maculopathy
every 3 years and every 2 years, respectively, and those at low risk every 5 years, was the most
cost-effective option using data from Gloucestershire.
8. The rate of detection of referable DR is elevated in those who were not screened promptly after
diagnosis of type 2 diabetes.
9. We have previously shown (outside this project) that there are patients with diabetes unknown to
screening programmes and that some of these have referable DR.52 This project has shown that
GP2DRS or similar software to extract demographic and risk factor data from primary care is necessary.
10. We found different rates of progression to STDR between patients with type 1 and type 2 diabetes.
11. We compared patients recently diagnosed with type 2 diabetes in the Gloucestershire screening
programme with patients recruited to the UKPDS, a large, multicentre, randomised clinical trial in
newly diagnosed type 2 diabetes patients which reported in 1998. Fewer patients in this screening
programme have DR and fewer have referable DR. Fewer are hyperglycaemic, more are hypertensive
and they are heavier than newly diagnosed patients recruited to UKPDS.
12. Our study did have some difficulties because of the withdrawal of Coventry and Warwickshire and the
fact that the ethnicity coding was incomplete in the other two screening programmes used to validate
the data. Some GPs recorded no or very little ethnicity data. Because of this, there were not enough
patients within each ethnic group to validate the models within the ethnic group. This is the reason
for our recommendation that the models need to be validated in data from areas where ethnicity
coding is accurate.
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13. This study was undertaken before the vascular endothelial growth factor (VEGF) inhibitor
Ranubizumab (Lucentis®, Novartis) and other novel agents were in widespread use. NICE approval for
the use of Ranubizumab occurred in April 2013; treatment clinics were not set up in Gloucestershire
until June 2013 and the cost-effectiveness data for treatment were collected between January 2013
and May 2014. These treatments were only just commencing towards the end of this period and if
more maculopathy patients had received intravitreal VEGF inhibitor treatment, this would have had an
impact on the results of the cost-effectiveness analysis.
In addition, the cost-effectiveness analysis was undertaken from data within the Gloucestershire DESP,
which has a unique cohort of patients who are a stable population and who have had a long-standing
screening programme and relatively well controlled HbA1c and blood pressure compared with some other
parts of the UK; hence, the analysis does need to be confirmed in other areas.
Recommendations
This project recommends that:
1. software to identify patients with diabetes in primary care and to provide or extract promptly
demographic and risk factor data to screening programmes is required
2. patient groups and stakeholders be consulted before any screening interval changes are introduced
3. all diabetic eye screening programmes record the date of diagnosis of diabetes and have access to
recent HbA1c results, in addition to the result of grading from the previous SE. Ethnicity and type of
diabetes should also be recorded
4. the risk stratification models should be validated in other eye screening programmes (inside and outside
England) to identify risk groups
5. misclassification of photographic grading (i.e. grading error rates) needs to be evaluated in all local eye
screening programmes
6. extended screening intervals should only be implemented by local programmes where grading
misclassification rates have been evaluated and are shown to be acceptably low (once the threshold has
been identified as outlined in Future work)
7. the knowledge arising from this project about progression and misgrading matrices are used to inform
quality assurance processes in screening
8. data from patients with mild NPDR (R1M0) in just one eye are reported independently of patients with
R1M0 in both eyes in DESP reports
9. the effectiveness and cost-effectiveness of this model is tested in other populations.
Future work
This project has identified the following areas for future research:
1. investigate strategies to improve knowledge about risk of DR to the national programme, screening
programmes, patients, HES, primary care and diabetes services. This would include investigating grading
misclassification rates in local programmes and determining acceptable ranges
2. investigate strategies to increase uptake in those with a poor attendance record
3. determine whether extending the screening interval in patients in low-risk groups alters their behaviour
over self-care of their diabetes or their attendance at subsequent screening events
4. investigate whether using the more granular information from feature-based grading (implemented in
England from 2013) will enable better identification of those at risk of progression to STDR and
improve the sensitivity and specificity of screening
CONCLUSIONS
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5. data analysis and modelling to identify patients with diabetes who might safely be screened only once
(‘screen once and forget’)
6. evaluate the clinical effectiveness and cost-effectiveness of this model in other populations
outside Gloucestershire
7. evaluate the use of automated grading to reduce grading misclassifications and further improve the
reliability of grading as a tool to provide personalised screening intervals.
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l Paper(s) on the cost-effectiveness of assigning diabetic patients to differing diabetic retinopathy
screening intervals (from Phases 4).
Data sharing statement
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Patient Information Advisory Group approval of consent model
The National Screening Programme for Diabetic Retinopathy (‘NSC DR’) approached the Patient Information
Advisory Group (PIAG) for advice on whether or not it was necessary to make a full application for Section 60
support. A decision was taken in December 2004 by PIAG and has been minuted as follows:
Diabetic retinopathy screening
The PIAG considered a request from the National Retinopathy Screening Programme for clarification
about whether Section 60 support was required for the programme as information would need to be
shared across several PCTs, hospital clinics and general practices. There had been reluctance on the
part of some data controllers to release patient information to the screening programme because of
confusion about this. The Advisory Group agreed that call and recall for retinopathy screening was
part of the care pathway. As such, consent to sharing relevant data could be implied from information
about how patient information is used by the retinopathy screening programme, being provided to
patients, and by making it clear patients had the right to opt out. There was therefore no requirement
to apply for Section 60 support.
The PIAG was also asked for their views on a consent model for the transfer of risk factor data within the
GP2DRS project, a national project of electronic transfer of demographic and risk factor data between
general practices and screening services in England.
The PIAG agreed that all patients should have the following letter sent to them prior to screening attendance,
that there would be implied consent for risk factor data transfer if they attended for screening and did not
inform the programme staff or general practice staff that they did not want risk factor data transferred.
The data used in this study will not identify individual patients. It will be pseudo-anonymised so that
grading data can be matched with risk factor data and then the analysis will be anonymised to
analytical staff.
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